# 2025年12月13日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 通过患者来源类器官个体化预测骨肉瘤化疗疗效：与生存和肿瘤增殖潜能的相关性研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41382267)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41382267
**DOI：** 10.1186/s13046-025-03541-1

### 第一部分 原文与翻译

**英文原标题：** Personalized prediction of chemotherapy efficacy in osteosarcoma through patient-derived organoids: correlation with survival and tumor proliferation potential.

> **英文摘要：**
> BACKGROUND: Neoadjuvant chemotherapy (NAT) is the standard treatment for osteosarcoma (OS), but patient responses vary, and conventional imaging or pathology offers limited predictive accuracy. Patient-derived organoids (PDOs) are promising models for assessing drug sensitivity and tumor viability ex vivo. This study evaluated the potential of PDO-based drug sensitivity testing and organoid formation potential (OFP) to predict therapeutic outcomes in OS.
> 
> METHODS: Tumor samples from OS patients collected before and after NAT were cultured as 3D PDOs. Chemosensitivity to first-line agents was quantified via a cell inhibition weighted score (CIWS), whereas OFP was used to reflect residual tumor viability. Clinical response was assessed via RECIST 1.1 and, for the primary analysis, dichotomized as responder (CR+PR+SD) versus nonresponder (PD); survival (OS/DFS) was tracked for up to 5 years. Correlations between PDO metrics and clinical outcomes were analyzed.
> 
> RESULTS: PDOs were established from 31 samples (18 pre-NAT samples and 13 post-NAT samples), including 8 paired pre/post-NAT samples. CIWS predicted NAT response assessed by RECIST 1.1 with 83.3% accuracy (pre-NAT, 15/18; 95% CI 58.6-96.4) and 5-year DFS with 84.6% accuracy (post-NAT, 11/13; 95% CI 54.6-98.1). With predefined CIWS/OFP cutoffs, Kaplan-Meier analyses showed longer DFS/OS in CIWS-sensitive and OFP-II/III (low growth) groups (P<0.05).
> 
> CONCLUSIONS: PDOs demonstrated promise as an ex vivo approach to evaluate whether ex vivo chemosensitivity and residual tumor viability measured by PDOs are associated with imaging response and 5-year survival. Their correlation with clinical outcomes highlights the potential of PDO testing to complement existing evaluation methods and to inform individualized treatment strategies.

> **中文摘要：**
> 背景：新辅助化疗（NAT）是治疗骨肉瘤（OS）的标准方案，但患者的反应差异显著，而传统影像学或病理学评估的预测精度有限。患者来源类器官（PDOs）作为一种离体模型，在评估药物敏感性和肿瘤活性方面具有潜力。本研究旨在评估基于PDO的药物敏感性检测及类器官形成潜能（OFP）对骨肉瘤治疗结局的预测价值。
> 
> 方法：收集骨肉瘤患者在NAT前后获得的肿瘤样本，并培养为三维PDO。通过细胞抑制加权评分（CIWS）量化其对一线药物的化疗敏感性，而OFP用于反映残余肿瘤活性。临床反应依据RECIST 1.1标准评估，并在主要分析中分为应答者（CR+PR+SD）与无应答者（PD）两组；总体生存期（OS）及无病生存期（DFS）随访最长5年。随后分析PDO指标与临床结局之间的相关性。
> 
> 结果：共从31份样本（18份NAT前样本和13份NAT后样本）中建立PDO，其中包括8对配对的前后NAT样本。基于RECIST 1.1评估，CIWS对NAT疗效的预测准确率为83.3%（NAT前，15/18；95% CI 58.6–96.4），对5年DFS的预测准确率为84.6%（NAT后，11/13；95% CI 54.6–98.1）。在预设的CIWS/OFP阈值下，Kaplan–Meier分析显示CIWS敏感组及OFP-II/III（低生长）组患者具有较长的DFS/OS（P<0.05）。
> 
> 结论：PDO作为一种离体评价体系，显示出评估化疗敏感性及残余肿瘤活性的潜力，其结果与影像学应答及5年生存率相关。该相关性提示PDO检测可作为现有评估方法的有益补充，为个体化治疗策略提供参考。

### 第二部分 AI 大师评价

本研究聚焦于利用患者来源类器官（PDO）模型预测骨肉瘤患者对新辅助化疗的反应及长期生存，具有重要的转化医学意义。研究设计通过量化化疗敏感性（CIWS）和类器官形成潜能（OFP）并与RECIST反应及生存结局相关联，展示出较高的预测准确率。结果支持PDO检测作为离体预测工具的可行性，可补充现有影像和病理评估。其创新之处在于结合PDO生物学特征与临床结局，揭示潜在个体化治疗价值，但样本量较小及实验复杂性可能限制其广泛推广。

---

## 2. 环状RNA ZFAND6抑制胃癌转移并降低对酪氨酸激酶抑制剂治疗的耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41382223)
**期刊：** Molecular cancer
**PMID：** 41382223
**DOI：** 10.1186/s12943-025-02478-5

### 第一部分 原文与翻译

**英文原标题：** CircZFAND6 suppresses gastric cancer metastasis and reduces resistance to TKI therapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要信息。

### 第二部分 AI 大师评价

该研究聚焦于环状RNA ZFAND6在胃癌进展中的作用，揭示其在抑制肿瘤转移及增强酪氨酸激酶抑制剂疗效方面的潜能。虽然缺乏摘要细节，但标题显示研究可能通过分子与功能实验验证CircZFAND6的生物学机制。该工作有助于深入理解癌症耐药性的环状RNA调控机制，具有潜在治疗意义。不过，具体机制和临床转化价值仍需进一步研究验证。

---

## 3. 乳腺癌中同工酶多样性缺失揭示的代谢协同脆弱性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41382155)
**期刊：** Genome medicine
**PMID：** 41382155
**DOI：** 10.1186/s13073-025-01573-y

### 第一部分 原文与翻译

**英文原标题：** Collateral metabolic vulnerabilities unveiled by loss of isozyme diversity in breast cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该研究聚焦于乳腺癌代谢适应机制，探讨同工酶多样性减少所导致的代谢网络脆弱性。题目暗示作者通过系统层面分析，识别出因代谢酶谱收缩而产生的代谢瓶颈和潜在治疗靶点。此类研究有助于揭示癌细胞代谢可塑性的进化代价，但尚需实验验证其在不同乳腺癌分型中的普适性与临床意义。总体而言，该研究具有新颖的代谢系统生物学视角与潜在转化价值。

---

## 4. 单细胞分辨率下CD8 T细胞衰竭在免疫检查点抑制剂耐受中的转录动态研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41382107)
**期刊：** Molecular cancer
**PMID：** 41382107
**DOI：** 10.1186/s12943-025-02468-7

### 第一部分 原文与翻译

**英文原标题：** Transcriptional dynamics of CD8 T-cell exhaustion in immune checkpoint inhibitor resistance at single-cell resolution.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于免疫检查点抑制剂（ICI）耐药过程中CD8 T细胞衰竭的转录调控变化，强调利用单细胞测序解析细胞状态转变的动态机制。该主题体现出研究团队对肿瘤免疫治疗耐药机制的深入探索。尽管目前摘要缺失，但研究标题显示其可能运用了高分辨率的单细胞转录组学技术，为理解T细胞衰竭的时间与空间维度提供关键线索。然而，具体结果与机制阐述尚需原文进一步确认。

---

## 5. 癌症诊断专利格局的绘制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381909)
**期刊：** Nature biotechnology
**PMID：** 41381909
**DOI：** 10.1038/s41587-025-02935-y

### 第一部分 原文与翻译

**英文原标题：** Mapping the patent landscape of cancer diagnostics.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文发表于《Nature Biotechnology》，核心目标是系统性地绘制癌症诊断领域的专利格局。研究可能整合了专利数据分析与生物医学技术趋势跟踪，旨在揭示该领域的创新热点与竞争态势。其创新性在于利用专利情报框架审视癌症诊断技术的发展路径，为研发策略和政策制定提供参考。然而，由于缺乏摘要，具体方法与数据来源仍需进一步查证。

---

## 6. USP10 通过调控 IGF2BP3-STEAP3 促进胰腺癌细胞增殖及吉西他滨耐药。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381842)
**期刊：** Oncogene
**PMID：** 41381842
**DOI：** 10.1038/s41388-025-03654-z

### 第一部分 原文与翻译

**英文原标题：** USP10 promotes cell proliferation and gemcitabine resistance in pancreatic cancer by the regulation of IGF2BP3-STEAP3.

> **英文摘要：**
> Gemcitabine resistance remains a major obstacle in the treatment of pancreatic adenocarcinoma (PDAC). Through gain- and loss-of-function experiments, we identified USP10 as a positive regulator of tumor growth and gemcitabine resistance. Mechanistically, we demonstrate that USP10 stabilizes IGF2BP3 by removing its K48- and K63-linked ubiquitin chains, thereby inhibiting proteasomal degradation. The stabilized IGF2BP3 binds to and enhances the stability of STEAP3 mRNA in an m⁶A-dependent manner. Upregulation of STEAP3 suppresses ferroptosis by increasing glutathione levels and reducing lipid peroxidation, ultimately promoting tumor proliferation and gemcitabine resistance. Our study identifies the USP10-IGF2BP3-STEAP3 axis as a critical mechanism underlying chemoresistance in pancreatic cancer, suggesting that targeting USP10 may offer a promising therapeutic strategy for overcoming gemcitabine resistance.

> **中文摘要：**
> 吉西他滨耐药仍然是胰腺腺癌（PDAC）治疗中的主要障碍。通过功能获得和丧失实验，我们鉴定出 USP10 是肿瘤生长和吉西他滨耐药的正向调控因子。从机制上，我们证实 USP10 通过去除 IGF2BP3 上 K48 和 K63 连接的泛素链，从而抑制其蛋白酶体降解，进而稳定 IGF2BP3。被稳定的 IGF2BP3 以 m⁶A 依赖的方式结合并增强 STEAP3 mRNA 的稳定性。STEAP3 的上调通过增加谷胱甘肽水平并减少脂质过氧化来抑制铁死亡，最终促进肿瘤增殖和吉西他滨耐药。我们的研究揭示了 USP10-IGF2BP3-STEAP3 轴是胰腺癌化疗耐药的关键机制，并提示以 USP10 为靶点可能成为克服吉西他滨耐药的潜在治疗策略。

### 第二部分 AI 大师评价

该研究旨在阐明胰腺癌中吉西他滨耐药的分子机制。作者通过功能实验确立了脱泛素酶 USP10 促进肿瘤增殖和耐药的作用，并揭示其通过稳定 IGF2BP3，从而增强 STEAP3 mRNA 稳定性，抑制铁死亡。研究构建了 USP10–IGF2BP3–STEAP3 轴这一新的耐药调控通路，具有机制创新性。其局限在于尚需更多临床样本及药物靶向验证来支持其转化潜力。

---

## 7. 短期限热摄入期间雄性小鼠的肝脏代谢重编程涉及增强的糖皮质激素节律

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381594)
**期刊：** Nature communications
**PMID：** 41381594
**DOI：** 10.1038/s41467-025-67228-z

### 第一部分 原文与翻译

**英文原标题：** Hepatic metabolic reprogramming in male mice during short-term caloric restriction involves enhanced glucocorticoid rhythms.

> **英文摘要：**
> Caloric restriction prolongs lifespan and preserves health across species, with feeding times synchronized to day-night cycles further maximizing benefits. However, the mechanisms linking diet, diurnal rhythms, and lifespan remain unclear. In mice, the time point most strongly tied to dietary effects on lifespan coincides with the peak of glucocorticoid secretion (ZT12, lights-off). Caloric restriction raises circulating glucocorticoid hormone levels, implicating these signals as candidate mediators for its benefits. Here we show that in the liver, the glucocorticoid receptor (GR) is required for the metabolic response to caloric restriction. Hepatocyte-specific GR mutant males fail to mount this response, indicating that increased glucocorticoid amplitude is necessary for the adaptation. Using multiomics, we find that nutrient deprivation elicits a nuclear switch from active STAT signaling to increased FOXO1 activity, enabling GR to activate diet-specific gene expression programs. Our results suggest that glucocorticoid rhythms are crucial for caloric restriction-induced metabolic reprogramming.

> **中文摘要：**
> 限热饮食可延长寿命并在多个物种中维持健康，当进食时间与昼夜周期同步时，健康效益可进一步最大化。然而，饮食、昼夜节律与寿命之间的联系机制仍不清楚。在小鼠中，与饮食对寿命影响最密切相关的时间点恰好与糖皮质激素分泌峰值（ZT12，熄灯时刻）一致。限热饮食会升高循环糖皮质激素水平，提示这些信号可能是其益处的候选介导因素。本文表明，在肝脏中，糖皮质激素受体（GR）是限热饮食引发代谢反应所必需的。肝细胞特异性GR突变的雄性小鼠无法产生这种反应，说明增强的糖皮质激素振幅对适应反应至关重要。通过多组学分析，我们发现营养缺乏诱导了细胞核内由活跃的STAT信号向FOXO1活性增强的转换，使GR能够启动与饮食相关的特异性基因表达程序。我们的结果表明，糖皮质激素节律对于限热饮食诱导的代谢重编程具有关键作用。

### 第二部分 AI 大师评价

本研究聚焦于雄性小鼠在短期限热饮食下肝脏代谢的节律性重编程，揭示了糖皮质激素信号及其受体在此过程中的核心作用。作者通过多组学分析揭示了营养缺乏诱导的信号通路从STAT向FOXO1的转换，从而激活糖皮质激素受体介导的特异性转录程序。研究创新性地将昼夜节律与代谢调控及限热效应联系起来，深化了对代谢适应性调节机制的理解。其局限性在于以雄性小鼠为主体，性别差异及长期动态反应仍有待进一步研究。

---

## 8. 个体间疼痛敏感性的皮质脊髓特征标志

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381586)
**期刊：** Nature communications
**PMID：** 41381586
**DOI：** 10.1038/s41467-025-67132-6

### 第一部分 原文与翻译

**英文原标题：** A corticospinal signature for interindividual pain sensitivity.

> **英文摘要：**
> Pain sensitivity variations represent a critical frontier in pain neuroscience, where advanced neuroimaging has mapped cerebral correlates of nociception for decades, yet conventional brain-centric models persistently overlook the spinal cord's hub role in pain gating and amplification. Here we show that a corticospinal pain sensitivity signature, a pattern of functional connectivity from simultaneous corticospinal magnetic resonance imaging, predicts individual pain sensitivity and clinical pain. Trained on resting-state data and validated across independent healthy (n = 723) and patient cohorts (n = 46), the model generalized to new datasets, distinguished pain from non-pain, and outperformed brain-centric models. Crucially, transcranial magnetic stimulation perturbation revealed a causal axis where enhanced motor cortex-spinal connectivity directly changes pain perception (r = 0.55). These results indicate a previously unknown corticospinal biomarker that bridges laboratory pain measures and patient symptoms, providing insights into translating pain mechanisms from healthy individuals to clinical populations and informing neuromodulation approaches.

> **中文摘要：**
> 疼痛敏感性的差异代表了疼痛神经科学中的关键前沿领域。在过去几十年中，高级神经影像技术已绘制了伤害感受的脑部相关图谱，但传统的以大脑为中心的模型仍持续忽视脊髓在疼痛闸门及放大中的枢纽作用。在本研究中，我们展示了一种皮质脊髓疼痛敏感性特征标志——一种基于同时皮质脊髓磁共振成像的功能连接模式——能够预测个体的疼痛敏感性和临床疼痛。该模型以静息态数据进行训练，并在独立的健康个体组（n=723）和患者组（n=46）中得到验证，能够泛化至新的数据集，区分疼痛与非疼痛状态，并优于以大脑为中心的模型。关键的是，经颅磁刺激干预揭示了一条因果轴，其中增强的运动皮质-脊髓连接直接改变疼痛感知（r=0.55）。这些结果表明，存在一种此前未知的皮质脊髓生物标志物，它连接实验室的疼痛测量与患者症状之间的差距，为从健康人群向临床群体转化疼痛机制及制定神经调控策略提供了重要洞见。

### 第二部分 AI 大师评价

本文旨在揭示皮质脊髓通路在个体疼痛敏感性差异中的作用，通过联合磁共振成像提出并验证了一种可预测个体与临床疼痛的功能连接模式。研究利用大样本静息态数据构建模型，验证其跨人群的泛化能力，并利用经颅磁刺激干预确认皮质—脊髓耦合对疼痛感知的因果影响。该研究首次提出皮质脊髓疼痛敏感性生物标志物，为理解健康与疾病状态下的疼痛调控机制提供了新方向。其创新之处在于从系统层面整合脑与脊髓信号，但未来仍需进一步探讨模型在不同疼痛类型和临床场景的应用性。

---

## 9. 全身再生过程调动了重构后的胚胎基因调控网络逻辑

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381581)
**期刊：** Nature communications
**PMID：** 41381581
**DOI：** 10.1038/s41467-025-67196-4

### 第一部分 原文与翻译

**英文原标题：** Whole body regeneration deploys a rewired embryonic gene regulatory network logic.

> **英文摘要：**
> A long-held hypothesis in regeneration proposes that developmental processes are re-deployed during regeneration. To investigate this, we compared embryonic and regeneration gene regulatory networks (GRN) in the sea anemone Nematostella vectensis using transcriptomic time series spanning these two developmental trajectories. Here, we show that regeneration reuses cohorts of the embryonic genes along with a small set of genes whose expression dynamics are specific to regeneration. We identified co-expression modules that are either conserved between embryogenesis and regeneration or specific to regeneration, with the latter linked to cellular mechanisms such as apoptosis, tissue remodeling, and wound healing. Functional assays revealed that apoptosis and cWnt signaling pathways are partially MEK/ERK dependent, have largely distinct downstream targets but converge to coordinate regenerative responses. Collectively, these results indicate that regeneration in N. vectensis represents a partial redeployment and extensive rewiring of the embryonic GRN, reactivating developmental modules through a regeneration-specific network logic.

> **中文摘要：**
> 再生领域中一个长期存在的假说认为，发育过程在再生过程中被重新利用。为探究这一假说，我们利用覆盖两个发育轨迹的转录组时间序列，比较了海葵 Nematostella vectensis 的胚胎期与再生期基因调控网络（GRN）。我们发现，再生过程重新利用了部分胚胎基因群，同时还涉及一小部分在再生中特异表达动态的基因。我们鉴定出若干共表达模块，其中一类在胚胎发生与再生之间保守存在，另一类则为再生特异，并与细胞凋亡、组织重塑和创伤愈合等细胞机制相关。功能实验显示，细胞凋亡与 cWnt 信号通路部分依赖 MEK/ERK 通路，它们的下游靶基因大体不同，但最终在协调再生反应方面趋于汇合。总体而言，这些结果表明，N. vectensis 的再生过程体现为胚胎基因调控网络的部分再利用与广泛重构，通过再生特异的网络逻辑重新激活了发育模块。

### 第二部分 AI 大师评价

本研究以海葵 Nematostella vectensis 为模型，通过比较胚胎发育与再生阶段的基因调控网络，揭示了再生过程中胚胎发育程序的部分重用与网络重连。研究结合转录组时间序列与功能实验，系统刻画了再生特异的基因模块及其信号通路依赖关系。结果显示，细胞凋亡和 cWnt 信号在再生过程中共同参与但作用分化，体现出再生网络逻辑的独特性。该研究为理解动物再生能力的分子基础提供了重要框架，但仍需进一步解析不同细胞类型间的调控层级与时空动态。

---

## 10. B细胞–IgA–上皮轴增强抗肿瘤免疫并改善与HPV相关的阴茎鳞状细胞癌预后

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381565)
**期刊：** Nature communications
**PMID：** 41381565
**DOI：** 10.1038/s41467-025-67356-6

### 第一部分 原文与翻译

**英文原标题：** A B cell-IgA-epithelial axis enhances antitumor immunity and improves outcome in HPV-associated penile squamous cell carcinoma.

> **英文摘要：**
> Penile squamous cell carcinoma (PSCC) is a rare, aggressive malignancy, with HPV driving approximately 50% of cases and correlating with improved outcomes. In this study, we perform single-cell RNA sequencing on tumor microenvironment (TME) cells from 23 treatment-naive PSCC patients, including 11 cases reported previously, and validate our findings in a larger cohort of 85 patients. Our analysis reveals significant immune cell infiltration in PSCC, with HPV tumors exhibiting elevated levels of tumor-infiltrating B cells, plasma cells, tertiary lymphoid structures, and IgA secretion. A subset of malignant epithelial cells in HPV PSCC express the polymeric IgA receptor (PIGR), facilitating IgA transcytosis and inducing anti-tumor responses. Functional studies show that PIGR overexpression promotes tumor apoptosis and enhances immune responses, with these effects diminish in IgA-deficient mice. Elevated IgA and PIGR expression correlate with improved survival. These findings provide a single-cell atlas of the PSCC TME, highlighting the B cell-IgA-PIGR axis as a pivotal driver of antitumor immunity and clinical outcomes in HPV PSCC.

> **中文摘要：**
> 阴茎鳞状细胞癌（PSCC）是一种罕见且侵袭性强的恶性肿瘤，其中约50%的病例由人乳头瘤病毒（HPV）驱动，并与较好的预后相关。在本研究中，我们对来自23例未经治疗的PSCC患者（其中包括先前已报道的11例）的肿瘤微环境（TME）细胞进行了单细胞RNA测序，并在一个包含85例患者的更大队列中验证了研究结果。我们的分析显示，PSCC中存在显著的免疫细胞浸润，HPV阳性肿瘤表现出较高水平的肿瘤浸润性B细胞、浆细胞、第三级淋巴结构以及IgA分泌。HPV相关PSCC中的一部分恶性上皮细胞表达聚合型IgA受体（PIGR），促进IgA跨胞转运并诱导抗肿瘤反应。功能性研究表明，PIGR过表达可促进肿瘤细胞凋亡并增强免疫应答，而这些效应在缺乏IgA的小鼠中减弱。IgA和PIGR的高表达与更好的生存结局相关。这些发现提供了PSCC肿瘤微环境的单细胞图谱，强调了B细胞–IgA–PIGR轴在HPV相关PSCC抗肿瘤免疫与临床结局中的关键作用。

### 第二部分 AI 大师评价

该研究利用单细胞RNA测序揭示了HPV相关阴茎鳞癌肿瘤微环境中的免疫细胞组成特征，发现B细胞–IgA–PIGR轴在抗肿瘤免疫中起核心调控作用。PIGR的上调通过促进IgA转运和肿瘤细胞凋亡增强免疫反应，并与患者预后改善相关。研究创新地揭示了上皮–免疫细胞互作的新机制，为PSCC免疫治疗提供了潜在靶点。然而，其因动物模型和样本来源的局限仍需进一步验证临床转化可行性。

---

## 11. β-阻遏蛋白在G蛋白偶联受体内吞中的多重作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381542)
**期刊：** Nature communications
**PMID：** 41381542
**DOI：** 10.1038/s41467-025-67156-y

### 第一部分 原文与翻译

**英文原标题：** Multi-faceted roles of β-arrestins in G protein-coupled receptor endocytosis.

> **英文摘要：**
> The internalization of G protein-coupled receptors (GPCRs) is a key process limiting cell surface receptor activity, and possibly promoting their intracellular signaling. Dysregulation of this process has been implicated in various diseases. This process is known to result from the recruitment of β-arrestins (βarrs) to the active receptors, although some receptors do not require this for unclear reasons. Here, we clarify the importance of βarrs in the internalization of 60 different GPCRs. We show that βarrs are essential for agonist-induced internalization for only a third of the receptors, half of the GPCRs being partially dependent on βarrs or even independent for endocytosis. Furthermore, we develop several Förster resonance energy transfer (FRET)-based molecular interaction assays to elucidate the molecular mechanism of internalization of the glucagon-like peptide-1 receptor (GLP-1R). We show that GLP-1R internalizes mainly by a βarr-independent mechanism involving the direct binding of the clathrin adaptor protein complex-2 to the receptor. However, when this adaptor protein complex-2-dependent mechanism is affected, the GLP-1R internalization becomes βarr-dependent. It shows that multiple mechanisms regulate the internalization of a specific receptor. Our data highlight the various processes used to control cell surface GPCRs, and open novel possibilities to specifically control their signaling processes.

> **中文摘要：**
> G蛋白偶联受体（GPCR）的内化是限制细胞表面受体活性并可能促进其细胞内信号传导的关键过程。该过程的失调与多种疾病有关。众所周知，这一过程源于β-阻遏蛋白（βarrs）被招募至活化受体，但某些受体出于未明原因并不依赖这一过程。在本研究中，我们阐明了βarrs在60种不同GPCR内化中的重要性。我们的结果表明，βarrs仅对三分之一受体的激动剂诱导的内化是必需的，而约一半GPCR在内吞过程中部分依赖或完全不依赖βarrs。此外，我们开发了多种基于福斯特共振能量转移（FRET）的分子相互作用检测方法，以阐明胰高血糖素样肽-1受体（GLP-1R）内化的分子机制。结果表明，GLP-1R主要通过一种βarr非依赖性机制内化，该机制涉及受体与网格蛋白衔接蛋白复合物-2的直接结合。然而，当该复合物-2依赖机制受损时，GLP-1R的内化转而依赖βarr。这表明，特定受体的内化受到多种机制的调控。我们的数据揭示了控制细胞表面GPCR的多样性过程，并为特异性调控其信号传导开辟了新的可能。

### 第二部分 AI 大师评价

本研究系统解析了β-阻遏蛋白在G蛋白偶联受体内化过程中的多样作用。作者通过分析60种GPCR的内化依赖性，揭示了受体内吞存在βarr依赖性、部分依赖性和非依赖性三种模式，并利用FRET技术深入解析了GLP-1R的分子机制。研究发现受体可通过网格蛋白衔接复合物-2依赖或βarr依赖途径实现动态调控，展示了内化调控的复杂性。本研究为靶向调控GPCR信号通路提供了新的理论依据，但其生理相关性及在不同细胞类型中的普适性仍有待进一步研究。

---

## 12. 来自人体皮肤共生菌人表皮葡萄球菌的抗菌肽类物质可抵御皮肤致病菌。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381538)
**期刊：** Nature communications
**PMID：** 41381538
**DOI：** 10.1038/s41467-025-66259-w

### 第一部分 原文与翻译

**英文原标题：** An antimicrobial daptide from human skin commensal Staphylococcus hominis protects against skin pathogens.

> **英文摘要：**
> Coagulase-negative staphylococci are dominant human skin colonizers, producing natural products that shape the community and prevent pathogen colonization. The molecular mechanisms by which these natural products mediate interbacterial competition are not fully understood. Here, we identify a plasmid-borne daptide bacteriocin (hominicin) from a human skin isolate of Staphylococcus hominis, which features an unusual N-N-dimethyl-1,2-propanediamine C-terminus. Heterologous expression of the reconstituted biosynthetic loci yields a daptide product of the same molecular mass that exhibits antimicrobial activity against the skin pathogen Staphylococcus aureus, with amino-modified termini being essential for activity. Membrane permeability and voltage-clamp lipid bilayer experiments support a mechanism by which the daptide rapidly dissipates the transmembrane potential by forming peptidic channels. Additionally, we identify a cognate homI gene that confers resistance against membrane damage. Finally, the purified daptide effectively protects mouse skin from S. aureus-induced epicutaneous injury, as evidenced by reduced bacterial burden, inflammation, and transepithelial water loss, highlighting its therapeutic potential for treating bacterial skin infections. Our findings elucidate a mechanism of action, biosynthesis, and resistance for a staphylococcal bacteriocin belonging to a class of natural products called daptides.

> **中文摘要：**
> 凝固酶阴性葡萄球菌是人类皮肤上的主要定植菌群，它们能产生天然产物以塑造微生物群落并防止病原体定植。这些天然产物在介导细菌间竞争的分子机制尚未被充分理解。本研究从人体皮肤分离的表皮葡萄球菌中鉴定出一种质粒携带的肽类细菌素（hominicin），其特征为具有不寻常的N-N-二甲基-1,2-丙二胺C末端。将重新组装的生物合成基因簇进行异源表达后，获得的肽类产物与原产物具有相同的分子质量，并对皮肤病原菌金黄色葡萄球菌表现出抗菌活性，其中氨基修饰的末端对于活性至关重要。膜通透性及电压钳脂质双层实验结果支持该肽通过形成肽性通道快速消散跨膜电位的作用机制。此外，研究鉴定出一个同源的homI基因，可赋予细胞膜损伤抗性。最后，纯化的该肽在体内能够有效保护小鼠皮肤免受金黄色葡萄球菌诱导的表皮损伤，其表现为细菌负荷、炎症及跨上皮水分流失均显著减少，提示其在治疗细菌性皮肤感染中的潜在应用价值。本研究阐明了这种属于daptide类天然产物的葡萄球菌细菌素的作用机制、生物合成过程及耐受机制。

### 第二部分 AI 大师评价

该研究揭示了人类皮肤共生菌表皮葡萄球菌可产生一种新型抗菌肽分子，通过形成肽性通道破坏膜电位，从而抑制皮肤病原体的生长。研究采用生物信息学、异源表达及电生理实验等多种手段，系统解析了该肽的结构特征、作用机制及耐受基因。其在动物模型中显示出明确的皮肤保护作用，表明其具有潜在的治疗应用前景。研究的创新性在于发现并功能化验证了一种新型daptide类天然产物，同时详细揭示了其分子抗菌机制。局限性在于其临床转化效应及长期安全性仍需进一步验证。

---

## 13. scDrugMap：用于药物反应预测的大型基础模型基准评估

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381537)
**期刊：** Nature communications
**PMID：** 41381537
**DOI：** 10.1038/s41467-025-67481-2

### 第一部分 原文与翻译

**英文原标题：** scDrugMap: benchmarking large foundation models for drug response prediction.

> **英文摘要：**
> Drug resistance remains a major challenge in cancer treatment. While single-cell profiling offers unprecedented resolution for uncovercovering resistance mechanisms, the potential of emerging foundation models for drug response prediction at the single-cell level is still largely unknown. Here, we introduce scDrugMap, a unified framework featuring both Python toolkits and an interactive web server for benchmarking and predicting drug responses with state-of-the-art foundation models. scDrugMap evaluates eight single-cell foundation models and two large language models across 495,000 cells from 60 datasets, spanning diverse tissues, drugs, cancer types, and treatment conditions. In pooled-data evaluation, scFoundation delivered the strongest performance, particularly in tumor tissue. In cross-data analysis, UCE performed best after fine-tuning, while in zero-shot settings, scGPT achieved the highest accuracy. Together, scDrugMap provides the first systematic benchmark of foundation models for single-cell drug response prediction and offers a powerful, user-friendly platform to accelerate drug discovery and translational precision oncology.

> **中文摘要：**
> 药物耐药性仍然是癌症治疗中的主要挑战。尽管单细胞分析为揭示耐药机制提供了前所未有的分辨率，但新兴的基础模型在单细胞层面进行药物反应预测的潜力仍基本未知。在此，我们介绍了 scDrugMap，这是一套统一的框架，结合了 Python 工具包和交互式网络服务器，用于利用最先进的基础模型对药物反应进行基准测试和预测。scDrugMap 评估了八种单细胞基础模型和两种大型语言模型，涵盖来自 60 个数据集的 495,000 个细胞，范围包括多种组织、药物、癌症类型和治疗条件。在混合数据评估中，scFoundation 表现最强，尤其在肿瘤组织中。在跨数据分析中，UCE 经过微调后表现最佳，而在零样本条件下，scGPT 达到了最高的预测准确度。总体而言，scDrugMap 提供了首个针对单细胞药物反应预测的系统性基础模型基准评估，并提供了一个强大且用户友好的平台，以加速药物发现和精准肿瘤学的转化研究。

### 第二部分 AI 大师评价

本文提出了 scDrugMap 平台，首创性地将大型基础模型应用于单细胞层面药物反应预测的系统性基准评估。研究综合了多种模型、药物与组织来源数据，展示了不同模型在多任务条件下的性能差异，为模型优化与临床转化提供了参考。其创新在于融合单细胞数据与大模型评估框架，而局限性可能在于模型泛化性与实际临床应用之间仍需进一步验证。

---

## 14. Lypd6b缺失通过代谢重编程促进结直肠癌中CD8 T细胞介导的抗肿瘤免疫。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381524)
**期刊：** Nature communications
**PMID：** 41381524
**DOI：** 10.1038/s41467-025-67344-w

### 第一部分 原文与翻译

**英文原标题：** Lypd6b depletion promotes CD8 T cell-mediated anti-tumor immunity via metabolic reprogramming in colorectal cancer.

> **英文摘要：**
> Lymphocyte antigen-plasminogen activator urokinase receptor domain-containing protein 6B (Lypd6b) is a newly identified molecule associated with neuromodulation. However, the role of Lypd6b in regulating the tumor microenvironment and its impact on CD8 T cell-mediated antitumor immunity remain unknown. Here, we observe that Lypd6b expression is increased significantly in colorectal cancer (CRC) tumor tissues compared to normal tissues. Lypd6b is mainly expressed in CD8 T cells in tumor tissues. Lypd6b knockout (Lypd6b) mice are resistant to AOM/DSS-induced tumorigenesis. Furthermore, global deficiency or CD8 cell deficiency of Lypd6b inhibits MC38 or CMT-93 tumor growth and promotes the infiltration of CD8 T cells. Mechanistically, Lypd6b deficiency promotes activation and function of CD8 T cells in anti-tumor response with increased glycolysis and reduced oxidative phosphorylation in a PI3K/mTOR/LDHA pathway-dependent manner. Notably, Lypd6b deficient CD8 T cells have a more potent antitumor effect when combined with anti-PD1 antibody. Thus, Lypd6b as a negative regulator for T cell immunity promotes CRC development, providing a molecular target with therapeutic potential in CRC.

> **中文摘要：**
> 含有淋巴细胞抗原-纤溶酶原激活物尿激酶受体结构域的蛋白6B（Lypd6b）是一种新鉴定的与神经调节相关的分子。然而，Lypd6b在调控肿瘤微环境及其对CD8 T细胞介导的抗肿瘤免疫的影响尚不清楚。在本研究中，我们观察到，与正常组织相比，结直肠癌（CRC）肿瘤组织中Lypd6b的表达显著升高。Lypd6b主要在肿瘤组织中的CD8 T细胞中表达。Lypd6b敲除小鼠对AOM/DSS诱导的肿瘤发生表现出抵抗性。此外，全身性或CD8 T细胞特异性的Lypd6b缺失可抑制MC38或CMT-93肿瘤的生长，并促进CD8 T细胞的浸润。从机制上看，Lypd6b缺失通过PI3K/mTOR/LDHA通路依赖的方式，促进CD8 T细胞在抗肿瘤反应中的激活和功能表现，其特征为糖酵解增加和氧化磷酸化降低。值得注意的是，Lypd6b缺失的CD8 T细胞与抗PD1抗体联合使用时表现出更强的抗肿瘤效应。因此，Lypd6b作为T细胞免疫的负调控因子，促进了结直肠癌的发展，并为CRC治疗提供了具潜力的分子靶点。

### 第二部分 AI 大师评价

本文揭示了Lypd6b在结直肠癌免疫微环境中的新作用，指出其作为CD8 T细胞功能的负调控因子参与肿瘤进展。研究通过Lypd6b敲除模型和代谢分析，发现其缺失可促进糖酵解、增强CD8 T细胞活性并抑制肿瘤生长，且与抗PD1治疗具有协同效应。该研究在机制上明确了Lypd6b-PI3K/mTOR/LDHA通路的关键性，创新性地联系了代谢重编程与T细胞免疫调控。尽管仍需临床验证，但其为结直肠癌免疫治疗提供了潜在新靶点。

---

## 15. BPTF 通过增强染色质可及性并稳定 AR-FOXA1 相互作用来调控雄激素受体活性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381516)
**期刊：** Nature communications
**PMID：** 41381516
**DOI：** 10.1038/s41467-025-67329-9

### 第一部分 原文与翻译

**英文原标题：** BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interaction.

> **英文摘要：**
> BPTF, the scaffolding subunit of the nucleosome remodeling factor (NURF) complex, has been implicated in the progression of several malignancies, but its role in prostate cancer (PCa) remains unclear. Here, we demonstrate that BPTF is upregulated in castration-resistant prostate cancer (CRPC) and promotes disease progression. RNA-seq revealed that BPTF primarily enhances the expression of androgen receptor (AR) target genes. ChIP-seq showed that BPTF increases AR binding at promoters, enhancers and super-enhancers. ATAC-seq further demonstrated that BPTF increases chromatin accessibility to facilitate AR binding, in part through SMARCA1, a catalytic subunit of the NURF complex. Notably, BPTF/AR co-bound regions are highly enriched for FOXA1 motifs but only weakly enriched for AR motifs. We further show that BPTF forms a protein complex with AR and FOXA1, in which FOXA1 recruits the BPTF-AR complex to chromatin, while BPTF stabilizes the AR-FOXA1 interaction. Importantly, BPTF interacts with AR through its bromodomain, and a BPTF bromodomain inhibitor disrupts this interaction, impairs AR signaling and suppresses PCa cell growth. In summary, our findings establish BPTF as a critical regulator of AR activity by promoting chromatin accessibility and stabilizing the AR-FOXA1 complex, highlighting BPTF as a potential therapeutic target in prostate cancer.

> **中文摘要：**
> BPTF 是核小体重塑因子（NURF）复合物的支架亚基，已被认为与多种恶性肿瘤的进展有关，但其在前列腺癌（PCa）中的作用仍不清楚。在本研究中，我们证明 BPTF 在去势抵抗性前列腺癌（CRPC）中上调，并促进疾病进展。RNA-seq 分析显示，BPTF 主要增强雄激素受体（AR）靶基因的表达。ChIP-seq 结果表明，BPTF 增强了 AR 在启动子、增强子及超级增强子区域的结合。ATAC-seq 进一步证明，BPTF 通过提高染色质可及性以促进 AR 结合，这一过程部分依赖于 NURF 复合物的催化亚基 SMARCA1。值得注意的是，BPTF/AR 共结合的区域中富含 FOXA1 模体，而 AR 模体富集较弱。我们进一步显示，BPTF 可与 AR 和 FOXA1 形成蛋白复合物，其中 FOXA1 招募 BPTF-AR 复合物至染色质上，而 BPTF 稳定 AR-FOXA1 相互作用。重要的是，BPTF 通过其溴结构域与 AR 相互作用，而 BPTF 溴结构域抑制剂可破坏此相互作用，削弱 AR 信号传导并抑制前列腺癌细胞生长。综上所述，我们的研究结果确立了 BPTF 作为调控 AR 活性的关键因子，其通过促进染色质可及性并稳定 AR-FOXA1 复合物而发挥作用，提示 BPTF 是前列腺癌潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究聚焦 BPTF 在去势抵抗性前列腺癌中的功能，综合利用 RNA-seq、ChIP-seq 与 ATAC-seq 揭示其调控雄激素受体信号的机制。研究发现，BPTF 通过增强染色质可及性、促进 AR 结合及稳定 AR-FOXA1 蛋白复合物来强化 AR 转录活性。溴结构域介导的 BPTF-AR 相互作用是其发挥生物学功能的关键环节，抑制该结构域可阻断 AR 信号并抑制肿瘤生长。该研究在机制层面揭示了 BPTF 的致癌作用，并将其确立为潜在药物靶点，具有较高的生物学与临床转化价值。

---

## 16. 人T细胞白血病病毒衣壳蛋白的高分辨率分析揭示了未成熟病毒颗粒形态的洞见

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381513)
**期刊：** Nature communications
**PMID：** 41381513
**DOI：** 10.1038/s41467-025-67129-1

### 第一部分 原文与翻译

**英文原标题：** High-resolution analysis of the human T-cell leukemia virus capsid protein reveals insights into immature particle morphology.

> **英文摘要：**
> Infection with human T-cell leukemia virus type 1 (HTLV-1) can result in adult T-cell leukemia/lymphoma and HTLV-1 associated-myelopathy/tropical spastic paraparesis. The Gag polyprotein - the major structural protein - is crucial for driving virus particle assembly, with the capsid (CA) domain as the key determinant for Gag multimerization. Here, we characterize the immature CA lattice from immature virus particles by using cryo-electron microscopy and tomography (cryo-EM/ET). We report resolving the immature CA lattice to 3.4 Å resolution by single particle analysis (SPA). Our reconstruction reveals that the lattice is stabilized through a trimeric NTD inter-hexamer interface and a dimeric CTD inter-hexamer interface. Further analysis by cryo-ET reveals clear heterogeneity, notably the varying lattice curvatures and the varying distances from the CA layer to the membrane. Intriguingly, inositol hexakisphosphate (IP6) is dispensable for HTLV-1 immature particle assembly and proper immature lattice formation. These observations provide deeper insights into the molecular basis of HTLV-1 immature particle morphology as well as aid in revealing therapeutic targets.

> **中文摘要：**
> 人T细胞白血病病毒1型（HTLV-1）感染可导致成人T细胞白血病/淋巴瘤以及HTLV-1相关的脊髓病/热带痉挛性截瘫。Gag多蛋白作为主要的结构蛋白，在驱动病毒颗粒装配过程中至关重要，其中衣壳（CA）结构域是Gag多聚化的关键决定因素。在本研究中，我们利用冷冻电子显微镜与断层扫描技术（cryo-EM/ET）对来源于未成熟病毒颗粒的未成熟CA晶格进行了结构特征分析。我们通过单颗粒分析（SPA）将未成熟CA晶格解析至3.4 Å的分辨率。重建结果显示，该晶格通过三聚体NTD六聚体间界面以及二聚体CTD六聚体间界面实现稳定。进一步的冷冻断层分析揭示了明显的异质性，特别是在晶格曲率变化以及CA层与膜之间距离变化方面。值得注意的是，肌醇六磷酸（IP6）对HTLV-1未成熟病毒颗粒的装配及正确晶格形成并非必需。这些观察结果为揭示HTLV-1未成熟病毒颗粒形态的分子基础提供了更深刻的认识，并有助于发现潜在的治疗靶点。

### 第二部分 AI 大师评价

该研究以高分辨率冷冻电镜和断层成像技术解析了HTLV-1未成熟衣壳晶格的三维结构，系统揭示了其稳定机制及结构异质性。作者发现CA晶格通过特定的NTD和CTD相互作用稳定，并指出IP6在装配中并非必需，突破了既有认知。研究结果深化了对HTLV-1病毒装配分子机制的理解，为抗病毒药物设计提供了新的结构线索。研究的创新性在于首次实现对HTLV-1未成熟衣壳的3.4 Å级别分辨率重建，但潜在局限在于对动态装配过程的时间分辨率仍待进一步研究。

---

## 17. 通过VHL募集嵌合体实现内质网应激感受器IRE1的化学诱导降解

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381506)
**期刊：** Nature communications
**PMID：** 41381506
**DOI：** 10.1038/s41467-025-66382-8

### 第一部分 原文与翻译

**英文原标题：** Chemically-induced degradation of the endoplasmic-reticulum stress sensor IRE1 by a VHL-recruiting chimera.

> **英文摘要：**
> The endoplasmic-reticulum (ER) transmembrane protein IRE1 mitigates ER stress through kinase-endoribonuclease and scaffolding activities. Cancer cells often co-opt IRE1 to facilitate growth. An IRE1-RNase inhibitor has entered clinical trials; however, recent work uncovered a significant nonenzymatic IRE1 dependency in cancer. To fully disrupt IRE1, we describe a proteolysis-targeting chimera (G6374) that couples an IRE1-kinase ligand to a compound that binds the ubiquitin Cullin-RING Ligase (CRL) substrate receptor, VHL. G6374 induces a stable, cooperative interaction between IRE1 and VHL, driving K48-linked ubiquitination on two principal lysine residues in the IRE1-kinase domain and inducing proteasomal IRE1 degradation. Cryogenic electron microscopy and mutagenesis studies reveal a 2:2 IRE1:VHL ternary-complex topology and critical interactional features, informing future designs. G6374 blocks growth of IRE1-dependent cancer cells irrespective of their dependency mode, while sparing IRE1-independent cells. We provide a proof-of-concept for VHL-based degradation of an ER-transmembrane protein, advancing strategies to fully disrupt IRE1.

> **中文摘要：**
> 内质网（ER）跨膜蛋白IRE1通过其激酶-内切核糖核酸酶活性及支架功能缓解ER应激。癌细胞常常挟持IRE1以促进其生长。虽然一种IRE1-RNase抑制剂已进入临床试验，但最新研究揭示癌症中存在显著的非酶促IRE1依赖性。为彻底破坏IRE1，我们描述了一种靶向蛋白水解的嵌合体（G6374），该分子将IRE1激酶配体与可结合泛素Cullin-RING连接酶（CRL）底物受体VHL的化合物偶联。G6374可诱导IRE1与VHL形成稳定且协同的相互作用，在IRE1激酶结构域的两个主要赖氨酸残基上驱动K48连接型泛素化，从而引发蛋白酶体介导的IRE1降解。低温电子显微镜与突变研究揭示了2:2的IRE1:VHL三元复合物拓扑结构及关键相互作用特征，为未来分子设计提供参考。G6374能抑制依赖IRE1的癌细胞生长，而不影响对IRE1无依赖性的细胞。我们提供了一个通过VHL实现ER跨膜蛋白降解的概念验证，推动彻底破坏IRE1的新策略发展。

### 第二部分 AI 大师评价

该研究针对内质网应激传感器IRE1提出了创新性的化学降解策略。研究团队设计了VHL募集型靶向水解嵌合体G6374，可诱导IRE1的泛素化并介导其蛋白酶体降解。通过冷冻电镜与定点突变技术，揭示了IRE1-VHL复合物的三维构型与关键相互作用界面。该方法突破了仅针对IRE1酶活性的传统抑制思路，为多模式依赖癌症提供了全局性破坏方案。其创新性显著，但仍需进一步验证在体内模型中的安全性与特异性。

---

## 18. H3K36甲基化：表观基因组完整性的守护者

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381501)
**期刊：** Nature communications
**PMID：** 41381501
**DOI：** 10.1038/s41467-025-66365-9

### 第一部分 原文与翻译

**英文原标题：** H3K36 Methylation as a Guardian of Epigenome Integrity.

> **英文摘要：**
> H3K36 methylation is a key epigenetic mark with critical roles in development and disease. Here, we systematically dissect its functions using CRISPR-engineered mouse mesenchymal stem cells lacking combinations of the five H3K36 methyltransferases, culminating in quintuple knockout cells devoid of H3K36me2/3. We show that H3K36me2 influences enhancer activity, supports the expression of their target genes, and safeguards active genes from encroachment of the repressive marks, H3K27me2/3. In addition, we find that the loss of H3K36me triggers redistribution of large heterochromatic H3K9me3 domains into euchromatin, in part mediated by SUV39H1, leading to global epigenomic remodelling, constitutive heterochromatin erosion, and a collapse of 3D genome organization. Parallel analyses in human HNSCC cells overexpressing the H3K36M oncohistone reveal conserved disruptions to the epigenome and chromatin architecture. Together, these results establish H3K36 methylation as a pivotal regulator of chromatin state and genomic structure.

> **中文摘要：**
> H3K36甲基化是一种关键的表观遗传标记，在发育与疾病过程中具有重要作用。本文利用CRISPR技术构建缺失五种H3K36甲基转移酶不同组合的小鼠间充质干细胞，并最终获得缺乏H3K36me2/3的五重敲除细胞，以系统解析其功能。研究显示，H3K36me2能够影响增强子活性，支持其靶基因的表达，并保护活跃基因免受H3K27me2/3等抑制性修饰的侵蚀。此外，研究发现，H3K36甲基化的缺失会引发大块异染色质H3K9me3区域向常染色质重新分布，这一过程部分由SUV39H1介导，导致表观基因组的整体重塑、固有异染色质的侵蚀以及三维基因组结构的崩塌。对过表达肿瘤相关组蛋白突变体H3K36M的人类头颈部鳞状细胞癌（HNSCC）细胞的平行分析表明，这种对表观基因组与染色质结构的广泛破坏具有保守性。综上所述，本研究确立了H3K36甲基化在调控染色质状态与基因组结构中的核心作用。

### 第二部分 AI 大师评价

该研究通过多重H3K36甲基转移酶敲除体系，系统阐明了H3K36甲基化在维持表观基因组稳定性中的作用机制。作者结合小鼠干细胞与人类癌细胞模型，揭示H3K36甲基化在防止抑制标记侵入、维持染色质组织及3D基因组结构方面的关键调控功能。研究技术路线严谨、实验层次清晰，为理解染色质标记互作网络提供了新的机制依据。其创新性在于以多酶敲除策略揭示协同效应，但尚需进一步探索该机制在不同生理或病理情境中的普适性。

---

## 19. CTCF 通过耦合远程环挤出与扩散机制介导多样化的 Igκ 基因库。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381500)
**期刊：** Nature communications
**PMID：** 41381500
**DOI：** 10.1038/s41467-025-67438-5

### 第一部分 原文与翻译

**英文原标题：** CTCF couples long-range loop extrusion and diffusion to mediate a diverse Igκ repertoire.

> **英文摘要：**
> Dynamic genome folding is important for V(D)J recombination at the immunoglobulin kappa (Igκ) locus, which recombines Jκ and Vκ gene segments across a 3.2 Mb region in both deletional and inversional orientations. Chromatin loop extrusion and diffusion are considered two key mechanisms underlying Igκ locus folding, but how they coordinate remains unclear. Here we show that CTCF is a key regulator coupling loop extrusion and diffusion during Igκ V-J rearrangement, promoting recombination in both orientations across long genomic distances. Mechanistically, the CTCF N-terminus promotes long-range loop extrusion that facilitates distal Vκ usage by stabilizing cohesin against WAPL release, and also forms loop barriers enabling chromatin diffusion for inversional Vκ joining. In CTCF N-terminal-deficient B cells, defects in inversional Vκ joining are not restored by WAPL depletion but are instead largely rescued by a dCas9-blockade targeted to the Vκ-Jκ intergenic region, mimicking the CTCF barrier. Our findings thus highlight how CTCF coordinates distinct genome-folding mechanisms through its dual roles in cohesin stabilization and extrusion barrier formation to ensure the generation of a diverse Igκ repertoire.

> **中文摘要：**
> 基因组的动态折叠对于免疫球蛋白 κ（Igκ）位点的 V(D)J 重组至关重要，该过程在一个 3.2 Mb 区域内以缺失和倒位两种方向重组 Jκ 与 Vκ 基因片段。染色质环挤出与扩散被认为是驱动 Igκ 位点折叠的两种关键机制，但它们如何协调作用仍不清楚。在本研究中，我们发现 CTCF 是在 Igκ V–J 重排过程中耦合环挤出与扩散的关键调控因子，能够在远距离基因区间上促进两种方向的重组。从机制上看，CTCF 的 N 端通过稳定 cohesin 抗衡 WAPL 的释放，促进远程环挤出，从而有利于远端 Vκ 的利用；同时，它还能形成环障碍，促进染色质扩散以支持倒位取向的 Vκ 连接。在缺失 CTCF N 端的 B 细胞中，倒位型 Vκ 连接的缺陷不能通过 WAPL 缺失而修复，但可通过在 Vκ–Jκ 基因间区靶向布置的 dCas9 阻断（模拟 CTCF 障碍）获得显著恢复。我们的研究揭示了 CTCF 通过在 cohesin 稳定与环挤出障碍形成中的双重作用，协调不同的基因组折叠机制，从而确保生成多样化的 Igκ 基因库。

### 第二部分 AI 大师评价

该研究阐明了转录因子 CTCF 在调控免疫球蛋白 κ 位点 V(D)J 重组中的结构与功能双重作用。作者结合染色质构象和功能性实验，揭示 CTCF 的 N 端在环挤出与扩散协调中的关键调控地位，解释其对顺向与倒向重组的双向促进作用。此工作将环挤出动力学与染色质扩散机制整合，为理解抗体多样性形成的高阶染色质结构机制提供了新的视角。其创新性强，但是否存在其他辅助因子参与协调尚需进一步研究。

---

## 20. 转录因子与 cBAF 的共凝聚选择性调控染色质重塑及基因表达

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381493)
**期刊：** Nature communications
**PMID：** 41381493
**DOI：** 10.1038/s41467-025-67322-2

### 第一部分 原文与翻译

**英文原标题：** Co-condensation between transcription factor and cBAF selectively modulates chromatin remodeling and gene expression.

> **英文摘要：**
> Activation of gene transcription is a tightly coordinated process that requires the engagement of transcription factors (TFs) and chromatin remodelers, yet how these components integrate at specific genomic loci remains unclear. Here, we report that ARID1A, a key subunit of the chromatin remodeler cBAF complex, forms condensates through uniformly distributed tyrosine residues within its core intrinsically disordered region (IDR). A series of TFs which feature in the presence of tyrosine within their transcription activation domain (TAD), selectively interact with ARID1A through core IDR-TAD interaction, thereby enabling co-condensation at specific loci. Furthermore, we demonstrate that co-condensation between ARID1A and TFs, such as GATA2, is crucial for maintaining chromatin accessibility and activating genes essential for lung cancer cell proliferation. Collectively, our study establishes the essential role of ARID1A in spatial organization of TFs and cBAF through phase separation, and demonstrates that tyrosine-mediated selective TFs-cBAF co-condensation represents a pivotal mechanism for gene activation.

> **中文摘要：**
> 基因转录的激活是一个高度协调的过程，需要转录因子（TFs）与染色质重塑复合物的参与，但这些组分如何在特定基因组位点共同作用仍不清楚。在本研究中，我们发现染色质重塑复合物 cBAF 的关键亚基 ARID1A，可通过其核心本征无序区（IDR）内均匀分布的酪氨酸残基形成凝聚体。一系列在其转录激活结构域（TAD）中含有酪氨酸的转录因子，可通过核心 IDR–TAD 相互作用选择性地与 ARID1A 结合，从而在特定位点实现共凝聚。此外，我们证明了 ARID1A 与转录因子（如 GATA2）之间的共凝聚对于维持染色质可及性以及激活对肺癌细胞增殖至关重要的基因起关键作用。总体而言，本研究确立了 ARID1A 通过相分离在组织转录因子与 cBAF 空间分布中的核心作用，并表明由酪氨酸介导的选择性 TF–cBAF 共凝聚代表了一种驱动基因激活的关键机制。

### 第二部分 AI 大师评价

该研究聚焦于转录因子与 cBAF 染色质重塑复合物之间的相分离机制，揭示 ARID1A 通过本征无序区内的酪氨酸残基与特定转录因子发生共凝聚。研究结合分子生化分析与功能实验，阐明了 ARID1A–TF 共凝聚在维持染色质开放性及促进肺癌相关基因表达中的关键作用。其创新性在于提出了“酪氨酸介导的选择性共凝聚”这一新型调控模式，为解释基因激活的空间组织机制提供了新视角。研究的局限在于尚需阐明确切的结构基础及其在其他细胞类型中的普适性。

---

## 21. 早期胚胎发育过程中双链RNA感知被沉默。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381491)
**期刊：** Nature communications
**PMID：** 41381491
**DOI：** 10.1038/s41467-025-66352-0

### 第一部分 原文与翻译

**英文原标题：** Double stranded RNA sensing is silenced during early embryonic development.

> **英文摘要：**
> The type I interferon response is inactive during early mammalian development and becomes functional only after gastrulation. As a result, the totipotent and pluripotent embryonic stages remain susceptible to pathogens, including viruses. Here, we demonstrate that pluripotent mouse embryonic stem cells suppress the RIG-I-like receptor sensing pathway by silencing the expression of the double stranded RNA sensor MDA5. This silencing is necessary to avoid the recognition of double stranded RNAs of endogenous origin, which accumulate in mouse embryonic stem cells. Reintroducing MDA5 results in recognition of these endogenous double stranded RNAs and triggers the activation of the IFN response through IRF3. The production of interferon alters the differentiation ability of mouse embryonic stem cells, and affects the pluripotency gene expression programme, as shown by epigenetic, transcriptomic and proteomic analyses. Further, we show that zebrafish also repress MDA5 expression in early development and lack early-stage interferon activation, and that inducing double-stranded RNA-mediated signalling at this stage results in developmental defects. Altogether, we conclude that silencing the RIG-I-like receptor pathway during early development is important in preventing aberrant immune recognition of endogenous double stranded RNAs, safeguarding normal development.

> **中文摘要：**
> I型干扰素反应在哺乳动物早期发育过程中处于不活跃状态，只有在原肠胚形成之后才变得具有功能。因此，全能性和多能性胚胎阶段对包括病毒在内的病原体仍然易感。本文证明，多能性小鼠胚胎干细胞通过沉默双链RNA感受器MDA5的表达来抑制RIG-I样受体的感知通路。这种沉默对于避免识别来源于内源性的双链RNA是必要的，因为此类RNA在小鼠胚胎干细胞中会积累。重新引入MDA5会导致这些内源性双链RNA被识别，并通过IRF3触发干扰素反应的激活。干扰素的产生改变了小鼠胚胎干细胞的分化能力，并影响其多能性基因表达程序，这一点在表观遗传学、转录组学和蛋白质组学分析中得到了验证。此外，我们还发现，斑马鱼在早期发育过程中同样抑制MDA5的表达，缺乏早期阶段的干扰素激活，而在此阶段诱导双链RNA介导的信号则会导致发育缺陷。综上所述，我们得出结论：早期发育阶段对RIG-I样受体通路的沉默对于防止内源性双链RNA被异常免疫识别并维持正常发育至关重要。

### 第二部分 AI 大师评价

本研究揭示了早期胚胎发育期间内源性免疫系统受控沉默的机制，阐释了多能干细胞通过抑制MDA5表达来避免识别自身RNA并启动干扰素反应的现象。研究创新性地将分子机制与发育调控相结合，利用多组学分析揭示免疫与多能性网络的交叉。其发现对理解先天免疫在胚胎发育中的阶段性控制具有重要意义，也提示过早激活抗病毒信号可能导致发育异常。未来可进一步探索这一机制在人类发育及干细胞应用中的潜在作用。

---

## 22. 人胰腺的三维成像显示胰岛大小和内分泌组成可能影响其在1型糖尿病中的丢失。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381473)
**期刊：** Nature communications
**PMID：** 41381473
**DOI：** 10.1038/s41467-025-66198-6

### 第一部分 原文与翻译

**英文原标题：** 3D imaging of human pancreas suggests islet size and endocrine composition influence their loss in type 1 diabetes.

> **英文摘要：**
> A high-definition description of pancreatic islets would prove beneficial for understanding the pathophysiology of type 1 diabetes (T1D), yet significant knowledge gaps exist in terms of their size, endocrine cell composition, and number in both health and disease. Here, 3-dimensional (3D) analyses of pancreata from control persons without diabetes (ND) demonstrate approximately 50% of islets are insulin-positive (INS + ) glucagon-negative (GCG-). Non-diabetic individuals positive for a single Glutamic acid decarboxylase autoantibody (GADA + ) yet at increased risk for disease consistently demonstrate endocrine features, including islet volume and cell composition, closely resembling the age-matched ND controls. In contrast, pancreata from individuals with short-duration T1D demonstrate significantly reduced islet density and a dramatic loss of INS + GCG- islets with preservation of large INS + GCG+ islets. The size and cellular composition of pancreatic islets may, therefore, represent influential factors that impact β-cell loss during T1D disease progression.

> **中文摘要：**
> 对胰岛的高清描述有助于理解1型糖尿病（T1D）的发病机制，然而在健康和疾病状态下，其大小、内分泌细胞组成和数量仍存在显著的认知空白。在本研究中，通过三维（3D）分析无糖尿病（ND）对照者的胰腺，发现约50%的胰岛为胰岛素阳性（INS+）、胰高血糖素阴性（GCG-）。非糖尿病但携带单一谷氨酸脱羧酶自身抗体（GADA+）且疾病风险升高的个体，其胰岛体积和细胞组成等内分泌特征与同龄ND对照密切相似。相反，短病程T1D患者的胰腺显示胰岛密度明显降低，并出现INS+GCG-胰岛显著丢失，而较大的INS+GCG+胰岛得以保留。因此，胰岛的大小和细胞组成可能是影响T1D疾病进展过程中β细胞丢失的重要因素。

### 第二部分 AI 大师评价

本研究利用三维成像技术系统描绘了人胰腺胰岛的结构特征，探索其在1型糖尿病发病过程中的变化。作者通过对健康者、GADA阳性高危个体及短病程T1D患者的胰岛比较分析，揭示胰岛大小与内分泌细胞组成与β细胞丢失密切相关。结果强调了INS+GCG-胰岛在疾病早期中的显著减少，而较大混合型胰岛仍被保留。这一工作创新地提供了立体结构层面的病理学证据，为T1D中β细胞保护策略提供了新的思路，但样本量和动态监测能力仍有待进一步加强。

---

## 23. 通过跨胞运输将尺寸可控纳米载体递送至营养不良骨骼肌可在小鼠中产生治疗效果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381470)
**期刊：** Nature communications
**PMID：** 41381470
**DOI：** 10.1038/s41467-025-66061-8

### 第一部分 原文与翻译

**英文原标题：** Transcytotic transportation of size-controlled nanocarriers into dystrophic skeletal muscle leads to therapeutic outcome in mice.

> **英文摘要：**
> Duchenne Muscular Dystrophy (DMD) is a lethal muscle-wasting disorder with limited therapeutic options. Although nano drug delivery offers promise, the biodistribution and access routes to dystrophic muscle remain poorly understood. Here we show that intravenously administered mesoporous silica nanoparticle (MSNP) carriers exhibit striking size-dependent biodistribution in male DMD mice. Small nanocarriers (50~100 nm) efficiently accumulate in skeletal muscle while avoiding hepatic and splenic sequestration, outperforming larger particles (200~300 nm). Importantly, we uncover that endothelial transcytosis, not passive vascular leakage, is the dominant and previously unrecognized route by which nanocarriers access dystrophic muscles. Further, we encapsulate tamoxifen, a repurposed drug, into optimized MSNPs. This intervention increases utrophin expression, reduces fibrosis, and diminishes myofiber necrosis, resulting in improved muscle health and strength. Our results establish size-tuned, transcytosis-enabled nanocarriers as a transformative strategy for targeted drug delivery to dystrophic muscle, paving the way for nanomedicine-based therapies in DMD and potentially other muscle disorders.

> **中文摘要：**
> 杜氏肌营养不良症（DMD）是一种致命的肌肉萎缩性疾病，现有治疗手段有限。尽管纳米药物递送显示出潜力，但其在营养不良肌肉中的生物分布及进入通路尚不清楚。本研究表明，静脉注射的介孔二氧化硅纳米颗粒（MSNP）载体在雄性DMD小鼠中表现出显著的尺寸依赖性生物分布。小尺寸纳米载体（50~100 nm）可高效聚集于骨骼肌，同时避免在肝脏和脾脏的滞留，优于较大颗粒（200~300 nm）。重要的是，我们发现内皮细胞的跨胞运输，而非被动血管渗漏，是纳米载体进入营养不良肌肉的主要且此前未被认识的途径。此外，我们将再利用药物他莫昔芬封装入优化的MSNP中。该干预可增加utrophin的表达，减少纤维化，并降低肌纤维坏死，从而改善肌肉健康和力量。我们的研究结果确立了基于尺寸调控与跨胞作用的纳米载体作为靶向递送至营养不良肌肉的变革性策略，为DMD及其他肌肉疾病的纳米药物疗法奠定了基础。

### 第二部分 AI 大师评价

该研究针对DMD肌肉药物递送中的瓶颈问题，系统揭示了纳米载体尺寸与生物分布、进入路径的关系。通过动物实验证实，小尺寸介孔二氧化硅纳米颗粒主要经由内皮跨胞运输进入营养不良骨骼肌，而非传统认为的血管渗漏机制。进一步将他莫昔芬封装后实现功能改善与组织修复，显示了在DMD治疗中的潜在转化价值。创新点在于首次明确跨胞运输在肌肉定向递送中的主导作用，为未来肌肉靶向纳米药物设计提供了新方向。

---

## 24. 基于计算机断层扫描图像的大规模生成式肿瘤合成以提升肿瘤识别性能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381469)
**期刊：** Nature communications
**PMID：** 41381469
**DOI：** 10.1038/s41467-025-66071-6

### 第一部分 原文与翻译

**英文原标题：** Large-scale generative tumor synthesis in computed tomography images for improving tumor recognition.

> **英文摘要：**
> AI-driven tumor recognition unlocks new possibilities for precise tumor screening and diagnosis. However, the progress is heavily hampered by the scarcity of annotated datasets, demanding extensive efforts by radiologists. To this end, we introduce FreeTumor, a Generative AI framework to enable large-scale tumor synthesis for mitigating data scarcity. Specifically, FreeTumor effectively leverages limited labeled data and large-scale unlabeled data for training. Unleashing the power of large-scale data, FreeTumor is capable of synthesizing a large number of realistic tumors for augmenting training datasets. We curate a large-scale dataset comprising 161,310 Computed Tomography (CT) volumes for tumor synthesis and recognition, with only 2.3% containing annotated tumors. 13 board-certified radiologists are engaged to discern between synthetic and real tumors, rigorously validating the quality of synthetic tumors. Through high-quality tumor synthesis, FreeTumor showcases a notable superiority over state-of-the-art tumor recognition methods, indicating promising prospects in clinical applications.

> **中文摘要：**
> 基于人工智能的肿瘤识别为精确的肿瘤筛查和诊断开辟了新的可能性。然而，由于标注数据集的稀缺，进展受到了严重限制，这要求放射科医生付出大量努力。为此，我们提出了 FreeTumor，这是一种生成式人工智能框架，可实现大规模肿瘤合成以缓解数据稀缺问题。具体而言，FreeTumor 有效地利用有限的标注数据和大规模的未标注数据进行训练。借助大规模数据的潜力，FreeTumor 能够合成大量逼真的肿瘤以增强训练数据集。我们整理了一个大规模数据集，包括 161,310 份计算机断层扫描（CT）体积数据，用于肿瘤合成和识别，其中仅有 2.3% 含有标注肿瘤。共有 13 名经认证的放射科医师参与判别合成肿瘤与真实肿瘤，以严格验证合成结果的质量。通过高质量的肿瘤合成，FreeTumor 展示了相较于当前先进肿瘤识别方法的显著优势，显示出在临床应用中的良好前景。

### 第二部分 AI 大师评价

本研究旨在通过生成式人工智能框架 FreeTumor 解决医学影像中肿瘤标注数据稀缺的问题。研究者构建了一个包含超过 16 万份 CT 影像的大型数据集，并利用有限标注与未标注数据联合训练，以实现高保真肿瘤图像合成。通过多位专业放射科医生的严格验证，FreeTumor 生成的肿瘤在真实性和识别效果上均表现出优越性。该方法显著提升了肿瘤识别模型的训练效率与性能，展现了在临床影像增强与数据扩增方面的创新潜力，但仍需进一步评估其在多样病种和跨设备场景下的泛化性。

---

## 25. 通过下调 CAMSAP3 介导的细胞骨架重塑驱动 NSCLC 细胞对奥希替尼的耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381443)
**期刊：** Cell death & disease
**PMID：** 41381443
**DOI：** 10.1038/s41419-025-08299-0

### 第一部分 原文与翻译

**英文原标题：** Cytoskeletal remodeling via CAMSAP3 downregulation drives resistance to osimertinib in NSCLC cells.

> **英文摘要：**
> Osimertinib, also known as AZD9291, is a highly potent and selective EGFR mutants (including exon 19 deletion, L858R/T790M) inhibitor that significantly inhibits EGFR phosphorylation signaling. However, acquired resistance to osimertinib is inevitable in the treatment of non-small cell lung cancer (NSCLC). Microtubules, key cytoskeletal components involved in intracellular cargo transport, mediate EGFR-endosomal recycling, yet their specific role in osimertinib resistance remains to be elucidated. In this study, we found that centrosomal microtubule formation was increased in osimertinib-resistant NSCLC cells, and calmodulin-regulated spectrin-associated protein 3 (CAMSAP3) was identified as the key molecule responsible for the change of microtubule morphology. Genetic modulation via CAMSAP3 silencing in both osimertinib-sensitive cells (in vitro) and xenograft models (in vivo) enhanced microtubule clustering and resistance to osimertinib, whereas CAMSAP3 overexpression in resistant cells partially restored microtubule organization and drug sensitivity. Furthermore, we demonstrated that full-length CAMSAP3 is essential for proper localization of the microtubule-dependent endosomal-lysosomal system. CAMSAP3 depletion caused EGFR translocation to the perinuclear microtubule organizing center (MTOC), thereby blocking plasma membrane recycling and promoting lysosomal degradation. These findings establish CAMSAP3 as a key regulator of EGFR signaling and osimertinib response in NSCLC, suggesting its therapeutic potential for overcoming drug resistance in lung cancer.

> **中文摘要：**
> 奥希替尼（亦称为 AZD9291）是一种对 EGFR 突变（包括外显子 19 缺失、L858R/T790M）具有高度效能和选择性的抑制剂，能显著抑制 EGFR 的磷酸化信号。然而，在非小细胞肺癌（NSCLC）治疗中，对奥希替尼的获得性耐药几乎不可避免。微管作为细胞内运输的重要细胞骨架成分，参与介导 EGFR 内体循环，但其在奥希替尼耐药中的具体作用仍有待阐明。本研究发现，在奥希替尼耐药的 NSCLC 细胞中，中心体微管形成显著增加，并鉴定出由钙调蛋白调控的谱系相关蛋白 3（CAMSAP3）是导致微管形态改变的关键分子。通过在奥希替尼敏感细胞（体外）和异种移植瘤模型（体内）中沉默 CAMSAP3，可增强微管聚集并促进奥希替尼耐药；相反，在耐药细胞中过表达 CAMSAP3 可部分恢复微管结构并增加药物敏感性。此外，我们证明，全长 CAMSAP3 对于维持微管依赖的内体-溶酶体系统的正确定位至关重要。CAMSAP3 缺失导致 EGFR 向细胞核周微管组织中心（MTOC）转移，从而阻断质膜循环并促进溶酶体降解。这些发现确立了 CAMSAP3 作为 EGFR 信号与奥希替尼应答关键调控因子的地位，并提示其在克服肺癌药物耐药中的潜在治疗价值。

### 第二部分 AI 大师评价

本文揭示了细胞骨架相关蛋白 CAMSAP3 在非小细胞肺癌细胞中调控奥希替尼耐药性的关键作用。研究通过细胞和动物模型实验证实，下调 CAMSAP3 可增强微管重组并促进药物耐受，而恢复表达则逆转这一过程。该工作创新性地将微管动力学与 EGFR 内体循环及耐药机制联系起来，为耐药性肺癌的精准治疗提供了新的分子靶点。其局限在于尚需在临床样本中进一步验证 CAMSAP3 相关调控网络的可行性与普适性。

---

## 26. 基于生物学信息的药物表征整合用于乳腺癌治疗的深度学习方法

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381442)
**期刊：** Nature communications
**PMID：** 41381442
**DOI：** 10.1038/s41467-025-66384-6

### 第一部分 原文与翻译

**英文原标题：** Biologically-informed integration of drug representations for breast cancer treatment using deep learning.

> **英文摘要：**
> Approximately 50% of breast cancer patients receiving neoadjuvant therapy do not achieve pathological complete response (pCR). Identifying personalized optimal therapeutic strategy is an unmet major challenge. Here, based on 4371 eligible patients from 31 datasets, we develop GDnet, an interpretable deep learning model integrating drug representations and tumor transcriptome profiles to predict the responses to neoadjuvant therapies and aid in selecting optimal treatment strategy. We demonstrate that GDnet significantly outperforms transcriptome-only model in predicting treatment response. Then we conduct two series of in-silico simulated clinical trials based on I-SPY2 trial and test datasets respectively and show that GDnet can significantly increase the pCR rate in all trials. Moreover, the odds ratios for pCR increase from 1.6 to 2.5 linearly as optimization intensifies. Overall, GDnet can function as a digital drug-testing surrogate to optimize treatment decision-making. This approach may have broader applications across various treatment settings and cancer types.

> **中文摘要：**
> 约有50%的接受新辅助治疗的乳腺癌患者未能达到病理完全缓解（pCR）。识别个体化的最优治疗策略仍是一项未满足的重要挑战。本研究基于来自31个数据集的4371名符合条件的患者，开发了GDnet这一可解释的深度学习模型，该模型整合了药物表征与肿瘤转录组特征，以预测新辅助治疗的反应并辅助选择最佳治疗策略。结果显示，GDnet在预测治疗反应方面显著优于仅基于转录组的模型。随后，我们基于I-SPY2试验及测试数据集分别开展了两组模拟临床试验，结果表明GDnet在所有试验中均能显著提高pCR率。此外，随着优化程度的增加，pCR的比值比从1.6线性上升至2.5。总体而言，GDnet可作为一种数字化药物测试替代工具，用于优化治疗决策。该方法有望在多种治疗场景和癌症类型中得到更广泛应用。

### 第二部分 AI 大师评价

本研究提出了一种创新的深度学习框架GDnet，通过将药物表征与肿瘤转录组相结合，实现了针对乳腺癌新辅助治疗反应的预测和治疗优化。其在多数据集上的表现显示出优于传统转录组模型的准确性，并通过模拟临床试验证实可提升pCR率。研究的关键创新在于将药物信息显式融入生物学指导的模型结构，提高了预测解释性和实用价值。潜在局限在于模型仍需在真实前瞻性临床试验中进一步验证。

---

## 27. DNMT1调控RASSF1A甲基化促进乳腺癌脑转移。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381440)
**期刊：** Cell death & disease
**PMID：** 41381440
**DOI：** 10.1038/s41419-025-08167-x

### 第一部分 原文与翻译

**英文原标题：** DNMT1 modulation of RASSF1A methylation enhances breast cancer brain metastasis.

> **英文摘要：**
> Epigenetic modifications, particularly DNA methylation, play a critical role in the metastatic progression of breast cancer. This study investigates the role of DNA methyltransferase 1 (DNMT1) in regulating the methylation of RASSF1A and its contribution to breast cancer brain metastasis. Using single-cell transcriptome sequencing of CTCs derived from in situ breast cancer models, DNMT1 was identified as a key promoter of tumor cell viability, migration, and invasion. RASSF1A was further validated as a direct target of DNMT1-mediated methylation. This regulatory interaction was confirmed through DNA methylation sequencing, methylation-specific PCR, and chromatin immunoprecipitation assays. These findings highlight the pivotal role of DNMT1-driven RASSF1A methylation in facilitating breast cancer metastasis to the brain, and suggest that targeting DNMT1 may represent a promising therapeutic approach for managing metastatic breast cancer.

> **中文摘要：**
> 表观遗传修饰，尤其是DNA甲基化，在乳腺癌转移进程中起着至关重要的作用。本研究探讨DNA甲基转移酶1（DNMT1）在调控RASSF1A甲基化中的作用及其对乳腺癌脑转移的贡献。通过对来源于原位乳腺癌模型的循环肿瘤细胞（CTCs）进行单细胞转录组测序，发现DNMT1是促进肿瘤细胞活性、迁移与侵袭的关键驱动因子。进一步验证发现，RASSF1A是DNMT1介导甲基化的直接靶基因。通过DNA甲基化测序、甲基化特异性PCR以及染色质免疫沉淀实验确认了这种调控相互作用。这些发现强调了DNMT1驱动的RASSF1A甲基化在促进乳腺癌脑转移中的关键作用，并提示针对DNMT1可能成为治疗转移性乳腺癌的有前景的策略。

### 第二部分 AI 大师评价

该研究聚焦于DNMT1通过调控RASSF1A甲基化促进乳腺癌脑转移的分子机制。研究采用单细胞转录组测序结合表观遗传学检测手段，系统揭示了DNMT1作为关键驱动因子在肿瘤细胞活性、迁移和侵袭中的核心作用。结果为理解乳腺癌脑转移的表观遗传调控机制提供了新的证据，并提出DNMT1作为潜在治疗靶点的临床价值。研究具有显著创新性，但仍需进一步验证其临床可转化性。

---

## 28. 在脂肪变性PTEN敲除背景下，BRUCE肝特异性敲除通过损伤线粒体代谢并激活STAT3促进MASLD/MASH的发展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381438)
**期刊：** Cell death & disease
**PMID：** 41381438
**DOI：** 10.1038/s41419-025-08294-5

### 第一部分 原文与翻译

**英文原标题：** BRUCE liver-KO enhances MASLD/MASH development in the steatotic PTEN-KO background by impairing mitochondrial metabolism and activating STAT3.

> **英文摘要：**
> The IAP BRUCE (Birc6) plays multifaceted roles in apoptosis inhibition, DNA repair, and autophagy. Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), affect up to 30% of the global population, yet their pathogenic mechanisms remain poorly understood. Given BRUCE's high expression in healthy livers and its downregulation in MASLD/MASH, we investigated its functional role using liver-specific BRUCE-KO and BRUCE/PTEN dual liver-KO (DKO) mouse models. PTEN liver-KO provides a steatotic background and reflects a major etiological factor. By 3 months, BRUCE liver-deficiency alone induces MASLD onset, but when combined with PTEN liver-KO, increases DNA damage, apoptosis, oxidative stress, and MASLD-to-MASH progression, characterized by inflammation and fibrosis. Mechanistically, PTEN liver-KO is known to drive hepatosteatosis through AKT-mediated de novo lipogenesis (DNL) (PTEN-KO → AKT → DNL). However, BRUCE liver-KO impairs mitochondrial fatty acid -oxidation (FAO), respiration and ATP generation (BRUCE→Mitochondria→FAO). This distinct yet complementary mechanism of action leads to a 'double hit' of excessive lipid synthesis (PTEN-KO) and impaired lipid clearance (BRUCE-KO), exacerbating steatosis. To elucidate the molecular driver of MASH progression, we found both deficiencies converge on STAT3 activation, a central regulator of inflammation and fibrosis. Further, targeted inhibition of STAT3 with TTI-101 alleviates MASH, establishing a BRUCE/PTEN-STAT3 pathogenic axis. Notably, this axis is conserved in humans, with co-downregulation of BRUCE and PTEN and concurrent STAT3 activation in MASLD/MASH patient specimens. Collectively, these findings establish BRUCE as a key metabolic safeguard against MASLD/MASH, reveal cooperative hepatoprotection by BRUCE/PTEN against MASLD/MASH, and suggest STAT3 inhibition as a targeted therapeutic strategy for BRUCE/PTEN-deficient patients.

> **中文摘要：**
> IAP 家族成员 BRUCE（Birc6）在抑制细胞凋亡、DNA 修复和自噬中发挥多重作用。代谢功能障碍相关脂肪性肝病（MASLD）及其进展型形式——代谢功能障碍相关脂肪性肝炎（MASH）影响了全球多达30%的人口，但其致病机制仍缺乏深入认识。鉴于 BRUCE 在健康肝脏中高表达而在 MASLD/MASH 中下调，我们利用肝特异性 BRUCE 敲除（KO）以及 BRUCE/PTEN 双肝敲除（DKO）小鼠模型研究其功能作用。PTEN 肝敲除为脂肪变性提供背景，并代表一个主要病因因素。到3个月时，单独的 BRUCE 肝缺失即可诱发 MASLD 的发生，而与 PTEN 肝敲除结合时，则进一步增加 DNA 损伤、细胞凋亡、氧化应激，并促进 MASLD 向 MASH 的进展，其特征为炎症与纤维化。在机制方面，已知 PTEN 肝敲除通过 AKT 介导的新生脂质生成（DNL）驱动肝脂肪变（PTEN-KO → AKT → DNL）。然而，BRUCE 肝敲除会损害线粒体脂肪酸β-氧化（FAO）、呼吸作用和ATP生成（BRUCE→线粒体→FAO）。这种不同但互补的作用机制导致“二次打击”：过度脂质合成（PTEN-KO）与脂质清除受损（BRUCE-KO），加重了脂肪变。为了阐明MASH进展的分子驱动，我们发现两种缺陷均在激活STAT3这一炎症与纤维化的核心调节因子处汇聚。此外，使用 TTI-101 靶向抑制 STAT3 可缓解 MASH，确立了 BRUCE/PTEN-STAT3 致病轴。值得注意的是，该致病轴在人类中亦被保守存在，在 MASLD/MASH 患者标本中观察到 BRUCE 和 PTEN 的共同下调及 STAT3 的共激活。总体而言，这些研究结果确立了 BRUCE 作为防御 MASLD/MASH 的关键代谢保护因子，揭示 BRUCE/PTEN 在抗MASLD/MASH中的协同肝保护作用，并提示对 BRUCE/PTEN 缺陷患者进行 STAT3 抑制可能成为一个有针对性的治疗策略。

### 第二部分 AI 大师评价

本文旨在阐明 BRUCE 在代谢相关脂肪性肝病（MASLD/MASH）发生发展中的作用机制。通过肝特异性单敲除和双敲除小鼠模型，研究者发现 BRUCE 缺失通过损伤线粒体脂肪酸氧化与能量代谢，加重由 PTEN 缺失引起的肝脂肪变，并促进炎症与纤维化进展。机制上，两者共同通过激活 STAT3 驱动 MASH 进展，而靶向抑制 STAT3 可显著缓解病变。该研究创新性地揭示了 BRUCE/PTEN-STAT3 信号轴在人类和小鼠间的保守性，为MASLD/MASH提供新的病理机制理解与潜在治疗靶点，但仍需通过临床研究验证其转化价值。

---

## 29. SARS-CoV-2 JN.1 衍生变异株（包括 JN.1.7、KP.2、KP.3 和 KP.3.1.1）的致病性、病毒学特征及免疫逃逸能力

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381428)
**期刊：** Nature communications
**PMID：** 41381428
**DOI：** 10.1038/s41467-025-66018-x

### 第一部分 原文与翻译

**英文原标题：** Pathogenicity, virological features, and immune evasion of SARS-CoV-2 JN.1-derived variants including JN.1.7, KP.2, KP.3, and KP.3.1.1.

> **英文摘要：**
> KP.3.1.1 became a dominant successor to JN.1 by the second half of 2024 but the intrinsic pathogenicity and virological feature of KP.3.1.1 remain incompletely understood. Here, we comprehensively evaluated the pathogenesis and characteristics of KP.3.1.1 in comparison to JN.1 and other JN.1-derived variants including JN.1.7, KP.2, and KP.3. The unique S31del mutation on KP.3.1.1 spike confers further evasion to the clinically authorized mAb Pemivibart and reduces convalescent serum neutralization efficiency. Structural analysis indicates that S31del induces novel glycosylation sites that facilitates evasion of neutralizing antibodies. We further reveal that S31del significantly enhances pseudovirus entry efficiency in all evaluated cell types including the human primary nasal epithelial cells. Nevertheless, the intrinsic pathogenicity of KP.3.1.1 is similar to JN.1 and KP.3, and higher than that of JN.1.7 and KP.2 in a male hamster model. Interestingly, the increased virus infectivity conferred by S31del in KP.3.1.1 spike is counterbalanced by the NSP10 S33C mutation. Overall, our study indicates that a single spike mutation can confer both enhanced immune escape and increased viral infectivity. The opposing effects of spike and non-spike mutations highlight the complex interplay of viral genomic elements in shaping their overall fitness, and reveal the high plasticity of coronavirus evolution.

> **中文摘要：**
> 到 2024 年下半年，KP.3.1.1 已成为 JN.1 的主要继任变异株，但其固有的致病性和病毒学特征尚未被完全理解。本研究系统评估了 KP.3.1.1 的发病机制及其特征，并与 JN.1 及其他 JN.1 衍生变异株（包括 JN.1.7、KP.2 和 KP.3）进行了比较。KP.3.1.1 棘蛋白上的独特 S31del 突变赋予其对临床批准的单克隆抗体 Pemivibart 更强的逃逸能力，并降低了康复者血清的中和效率。结构分析显示，S31del 可引发新的糖基化位点，从而促进其逃避中和抗体。进一步研究发现，S31del 能显著增强假病毒在所有检测的细胞类型（包括人原代鼻上皮细胞）中的进入效率。然而，在雄性仓鼠模型中，KP.3.1.1 的固有致病性与 JN.1 和 KP.3 相似，但高于 JN.1.7 和 KP.2。有趣的是，S31del 在 KP.3.1.1 棘蛋白上所赋予的感染性增强效应，会被 NSP10 S33C 突变所抵消。总体而言，本研究表明单个棘蛋白突变即可同时赋予增强的免疫逃逸能力和提高的病毒感染性。棘蛋白突变与非棘蛋白突变的相反效应突显了病毒基因组元件在整体适应性形成中的复杂相互作用，并揭示了冠状病毒进化的高度可塑性。

### 第二部分 AI 大师评价

本研究针对 SARS-CoV-2 JN.1 衍生变异株，系统比较了其主要代表 KP.3.1.1 的致病性与免疫逃逸特征。作者结合结构分析与病毒学实验，揭示了棘蛋白 S31del 突变通过改变糖基化模式增强免疫逃逸并提高病毒入侵效率，而 NSP10 S33C 突变则具有平衡效应。研究结果突出了单点突变在病毒适应性演化中的双重作用，深化了对新兴变异株生物学特性的理解。其创新性在于揭示棘蛋白与非棘蛋白突变间的拮抗平衡，但局限在于主要基于模型实验，仍需在人群中进一步验证。

---

## 30. 体内碱基编辑在人源化小鼠模型中挽救常染色体显性多囊肾病。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381416)
**期刊：** Nature communications
**PMID：** 41381416
**DOI：** 10.1038/s41467-025-65997-1

### 第一部分 原文与翻译

**英文原标题：** In vivo base editing rescues ADPKD in a humanized mouse model.

> **英文摘要：**
> Autosomal dominant polycystic kidney disease (ADPKD) is a genetic kidney disease, caused by mutations of the PKD1 and PKD2 genes, characterized by the development of renal cysts and extrarenal complications, such as cardiac hypertrophy. Recently, a revolutionary approach, adeno-associated virus (AAV) delivered CRISPR-Cas9 gene editing, has been developed to treat inherited diseases. However, the use of this technology in kidney diseases in vivo is challenged. In this study, we adapt one of the gene editing systems, adenine base editor (ABE9), to develop a broadly expressed and a kidney-specific promoter mediated base editors, and test the effects of these two systems delivered by AAV9 on preventing disease in humanized Pkd1 mice carrying an arginine (R) to cystine (C) mutation that mimics a mutation in ADPKD patients. We show that one dose of the broadly expressed dual ABE9-AAV9 treatment corrects the pathogenic variant in kidneys, hearts and livers, and result in delaying cyst growth, decrease heart hypertrophy and improve liver function. To confirm the specificity of the base editor system in kidneys, we show that one dose of the kidney specific promoter mediated dual-ABE9-AAV9 treatment corrects the Pkd1 gene mutation in the kidney, and not in the heart, resulting in delaying cyst growth in Pkd1 kidneys, supporting a promising strategy of using base editor to target specific organs. Treatment with ABE9 base editors mediated by either the broadly expressed or kidney specific promoter increased the survival rate of Pkd1 mice. These preclinical studies support a potential that single-dose genetic therapies may be through the correction of pathogenic variants to prevent ADPKD development in the clinic.

> **中文摘要：**
> 常染色体显性多囊肾病（ADPKD）是一种由PKD1和PKD2基因突变引起的遗传性肾脏疾病，其特征是肾囊肿形成及心脏肥大等肾外并发症。近年来，一种革命性的方法——腺相关病毒（AAV）递送的CRISPR-Cas9基因编辑技术——已被开发用于治疗遗传性疾病。然而，该技术在体内肾脏疾病中的应用仍面临挑战。本研究中，我们采用一种基因编辑系统——腺嘌呤碱基编辑器（ABE9），开发了广泛表达型和肾特异性启动子介导的碱基编辑器，并利用AAV9递送这两种系统，检测它们在携带精氨酸（R）到半胱氨酸（C）突变（模拟ADPKD患者突变）的Pkd1人源化小鼠中预防疾病的效果。我们发现，单次给予广泛表达型双ABE9-AAV9治疗可在肾脏、心脏和肝脏中校正致病变异，从而延缓囊肿生长，减轻心脏肥大并改善肝功能。为验证碱基编辑系统在肾脏的特异性，我们进一步发现，单次给予肾特异性启动子介导的双ABE9-AAV9治疗仅在肾脏内校正Pkd1基因突变，而不影响心脏，并能够延缓Pkd1小鼠肾囊肿的生长，支持通过碱基编辑实现特定器官靶向治疗的可行性。无论采用广泛表达型还是肾特异性启动子介导的ABE9碱基编辑器治疗，均可提高Pkd1小鼠的生存率。这些临床前研究结果表明，单剂量基因疗法通过校正致病突变，有望在临床上预防ADPKD的发生。

### 第二部分 AI 大师评价

该研究旨在探索利用AAV递送的ABE9碱基编辑系统纠正ADPKD致病突变的可行性与疗效。研究团队设计了广谱型和肾特异性两种编辑系统，并在携带人源化突变的Pkd1小鼠中验证。结果显示，两种方案均能有效纠正突变、抑制囊肿生长并延长小鼠寿命，尤其肾特异性系统展现出良好的组织靶向性。此研究为ADPKD等遗传性肾病的精准治疗提供了新的技术路径，但仍需进一步验证其长期安全性与临床转化可行性。

---

## 31. 携带无义突变型 p53 的小鼠频繁发生多中心或转移性肿瘤

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381412)
**期刊：** Cell death & disease
**PMID：** 41381412
**DOI：** 10.1038/s41419-025-08290-9

### 第一部分 原文与翻译

**英文原标题：** Mice carrying nonsense mutant p53 develop frequent multicentric or metastatic tumors.

> **英文摘要：**
> The TP53 tumor suppressor gene is mutated in a large fraction of human tumors. Close to 11% of TP53 mutations are nonsense mutations, causing premature termination of protein synthesis and expression of truncated inactive p53 protein. The most common TP53 nonsense mutation in human cancer is R213X. To study the impact of TP53 nonsense mutations in vivo, we generated mice harboring the Trp53 nonsense mutation R210X that corresponds to human TP53-R213X. Initially, Trp53 mice appear phenotypically normal, although the proportion of female Trp53 mice is dramatically reduced. Female homozygous mice are poor breeders and remain smaller and lighter than female heterozygous and wildtype littermates. Trp53 mice start to show tumors at 2.5 months of age, and their maximal lifespan is 8.5 months. Trp53 mice present tumors from 9 months of age, and by 16.5 months of age 50% of all heterozygous mice have developed overt tumors. 71% of tumors from Trp53 mice show loss of heterozygosity (LOH). Homozygous mice develop hematopoietic and mesenchymal tumors, most commonly T-cell lymphoma and leiomyosarcoma, and heterozygous mice develop hematopoietic, mesenchymal, epithelial and sex cord tumors, most commonly osteosarcoma and leiomyosarcoma. The tumor phenotype is similar to that of Trp53-null and Trp53-missense knock-in mice, although the Trp53 mice have a high rate of multicentric or metastatic tumors, and Trp53 mice have a longer overall survival than Trp53 missense mutant knock-in mice. Treatment of T-cell lymphoma cells from Trp53 mice with aminoglycoside G418 induces expression of full-length functional p53 and apoptotic cell death. Our new unique mouse model will allow further studies of the effects of Trp53 nonsense mutation in a multi-organ system and serve as a model for the Li-Fraumeni syndrome (LFS). It will also be valuable for preclinical evaluation of novel therapeutic strategies for targeting TP53 nonsense mutations in cancer.

> **中文摘要：**
> TP53 肿瘤抑制基因在相当大比例的人类肿瘤中发生突变。约 11% 的 TP53 突变属于无义突变，导致蛋白质合成提前终止，并产生截短且失活的 p53 蛋白。人类癌症中最常见的 TP53 无义突变是 R213X。为研究 TP53 无义突变在体内的影响，我们构建了携带 Trp53 无义突变 R210X 的小鼠模型，该突变对应于人类 TP53-R213X。最初，Trp53 小鼠表现为表型正常，但雌性 Trp53 小鼠的比例显著下降。纯合雌鼠繁殖能力差，体型较小且体重低于杂合及野生型同窝雌鼠。Trp53 小鼠自 2.5 个月龄起开始出现肿瘤，其最大寿命为 8.5 个月。Trp53 小鼠从 9 个月龄起出现肿瘤，到 16.5 个月龄时，50% 的杂合小鼠已发生明显肿瘤。Trp53 小鼠中 71% 的肿瘤表现出杂合性丢失（LOH）。纯合小鼠主要发生造血及间充质肿瘤，最常见的是 T 细胞淋巴瘤和平滑肌肉瘤；杂合小鼠则发生造血、间充质、上皮及性索肿瘤，最常见的是骨肉瘤和平滑肌肉瘤。其肿瘤表型与 Trp53 缺失型及 Trp53 错义突变敲入小鼠相似，但 Trp53 小鼠具有更高比例的多中心或转移性肿瘤，且其总体存活时间长于 Trp53 错义突变敲入型小鼠。将 Trp53 小鼠来源的 T 细胞淋巴瘤细胞用氨基糖苷类抗生素 G418 处理，可诱导全长、功能性 p53 表达并触发细胞凋亡。我们建立的新型独特小鼠模型可进一步用于研究 Trp53 无义突变在多器官系统中的作用，并可作为 Li-Fraumeni 综合征（LFS）的模型，同时为靶向癌症中 TP53 无义突变的新型治疗策略提供前临床评估平台。

### 第二部分 AI 大师评价

本研究旨在通过建立携带 Trp53 无义突变 R210X 的小鼠模型，探索 TP53 无义突变在体内的致瘤效应。研究者发现，该模型小鼠可在较早阶段发生多种肿瘤，尤其是多中心性或转移性肿瘤，其肿瘤谱系与 TP53 缺失或错义突变模型相似。实验进一步显示，G418 能恢复 p53 功能并诱导肿瘤细胞凋亡，提示无义突变可能具有可逆治疗潜力。该模型不仅为 Li-Fraumeni 综合征相关机制研究提供了重要工具，也为 TP53 无义突变靶向治疗的前临床开发奠定了基础。

---

## 32. 系统性 STING 激动剂治疗可驱动患有实体肿瘤犬只的干扰素刺激基因表达及后续细胞因子生成。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381219)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41381219
**DOI：** 10.1136/jitc-2025-013715

### 第一部分 原文与翻译

**英文原标题：** Systemic STING agonist therapy drives expression of interferon stimulated genes and downstream production of cytokines in dogs with solid tumors.

> **英文摘要：**
> BACKGROUND: Stimulator of interferon genes (STING) agonist drugs can induce expression of interferon stimulated genes (ISGs) and proinflammatory cytokine production aimed to enhance antitumor immunity. The purpose of the current study was to determine the safety, pharmacokinetic, and systemic and intratumoral pharmacodynamic properties of a novel, intravenously delivered STING agonist in client-owned dogs with cancer.
> 
> METHODS: GSK856, a small-molecule dimeric amidobenzimidazole STING agonist, was administered intravenously to dogs with naturally developing tumors. Patients received two doses of GSK856 1 week apart, followed by definitive-intent surgical tumor removal.
> 
> RESULTS: 19 dogs diagnosed with various solid tumor types, including malignant melanoma (oral mucosa, n=9; digit, n=1; conjunctiva, n=1), soft tissue sarcoma (5), rhabdomyosarcoma (1), oral fibrosarcoma (1), and mammary squamous cell carcinoma (1), were enrolled. Systemic pharmacokinetic analysis revealed rapid plasma clearance of GSK856 within 30 min of bolus administration. Clinical adverse events of fever, lethargy, and nausea were transient. Concurrent elevation in serum cytokines, including interleukin-6, was consistent with cytokine release syndrome following activation of the STING pathway. Transcriptional analyses of pretreatment and post-treatment blood and tumor tissue revealed robust induction of ISGs.
> 
> CONCLUSIONS: These data identify tolerated dose levels for a novel, intravenously delivered STING agonist compound that results in on-target effects in systemic and intratumoral immune responses in dogs with solid tumors.

> **中文摘要：**
> 背景：干扰素基因刺激因子（STING）激动剂药物能够诱导干扰素刺激基因（ISG）的表达及促炎性细胞因子产生，从而增强抗肿瘤免疫。本研究旨在确定一种新型静脉给药的 STING 激动剂在患癌犬只中的安全性、药代动力学特征，以及全身和肿瘤内药效学特性。
> 
> 方法：GSK856 是一种小分子二聚体酰胺苯并咪唑类 STING 激动剂，通过静脉注射给予自然发生肿瘤的犬只。受试犬每隔一周接受两次 GSK856 给药，随后进行根治性肿瘤外科切除。
> 
> 结果：共纳入 19 只被诊断为不同类型实体瘤的犬只，包括恶性黑色素瘤（口腔黏膜 n=9；趾部 n=1；结膜 n=1）、软组织肉瘤（5 例）、横纹肌肉瘤（1 例）、口腔纤维肉瘤（1 例）及乳腺鳞状细胞癌（1 例）。系统性药代动力学分析显示，GSK856 在推注给药后 30 分钟内迅速从血浆中被清除。临床不良事件包括发热、嗜睡和恶心，均为短暂性。血清细胞因子（如白介素-6）水平的同时升高与 STING 通路激活后出现的细胞因子释放综合征一致。治疗前后血液及肿瘤组织的转录组分析显示 ISG 表达显著上调。
> 
> 结论：这些数据确定了一种新型静脉给药 STING 激动剂的可耐受剂量，其可在患实体瘤犬只中诱导系统性及肿瘤内免疫应答的靶向效应。

### 第二部分 AI 大师评价

该研究评估了一种新型静脉给药 STING 激动剂 GSK856 在患癌犬只中的安全性与免疫活性。研究显示该药物具有可控的不良反应和快速的药代清除特征，同时显著诱导干扰素刺激基因及相关细胞因子表达。结果表明其在系统及肿瘤内均能产生明确的免疫活化作用，为 STING 类疗法的安全剂量探索提供了重要依据。研究创新之处在于通过自然肿瘤模型犬验证全身给药 STING 激动剂的可行性，但样本量有限，对长期疗效仍需进一步评估。

---

## 33. 激活先天免疫系统：一种靶向 CD47 和 CD24 的新型双特异性抗体用于选择性肿瘤清除

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381218)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41381218
**DOI：** 10.1136/jitc-2025-013283

### 第一部分 原文与翻译

**英文原标题：** Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance.

> **英文摘要：**
> BACKGROUND: Tumor-associated macrophages (TAMs) abundantly infiltrate tumors and possess potent antitumor capabilities. "Don't eat me" signals like CD47 allow tumors to evade macrophages and proliferate unchecked. CD47 is upregulated in many tumors and interacts with the SIRPα expressed on macrophages to restrict effector function. Similarly, CD24 interacts with the Siglec-10 on TAMs to inhibit engulfment. Despite their potential, there is still a lack of effective therapeutics targeting macrophages. Recent clinical trials targeting CD47 have demonstrated limited efficacy and significant side effects in solid tumors, primarily due to the expression of CD47 on healthy cells such as red blood cells (RBCs). We therefore developed novel anti-CD47 variable domain of heavy chain of heavy-chain antibodies (vHHs) with strong ligand-blocking activity while demonstrating minimal binding to RBCs and incorporated these vHHs to generate an anti-CD47/CD24 bispecific antibody that preserves Fc-effector function and achieves improved tumor targeting while maintaining the blockade of antiphagocytic signals elicited by both CD47 and CD24.
> 
> METHODS: Yeast display was employed to generate vHHs targeting CD47 and fully human monoclonal antibodies against CD24, respectively. The antigen binding epitopes of the vHHs to CD47 were predicted using AlphaFold3. Bispecific antibodies were designed, constructed, and characterized in vitro. Antitumor efficacy was evaluated in a human immune cell reconstitution mouse model, while safety was evaluated using a humanized syngeneic mouse model. Furthermore, the underlying mechanisms and alterations in tumor microenvironment were explored ex vivo.
> 
> RESULTS: VHHs targeting CD47 and a fully human antibody against CD24 were identified, all exhibiting potent ligand-blocking activity. The bispecific antibody BiAb-103C, engineered on a human IgG1 scaffold, had strong binding to CD47CD24 tumor cells and could effectively inhibit the CD47-SIRPα interaction. Fc-effector activity was observed towards CD24 (but not CD47) single-positive cells to promote phagocytosis and antibody-dependent cellular cytotoxicity of CD47CD24 tumor cells. In mice, antibody candidates demonstrated notable antitumor activity alongside favorable safety observations.
> 
> CONCLUSIONS: Our study presents the discovery of an anti-CD47/CD24 bispecific antibody that offers a promising therapeutic strategy to address the challenges associated with both the efficacy and safety of CD47-targeting agents, offers insight into macrophage-driven cancer immunotherapy, and could potentially provide a therapeutic option for patients non-responsive to immunotherapy.

> **中文摘要：**
> 背景：肿瘤相关巨噬细胞（TAMs）广泛浸润于肿瘤内，并具有强大的抗肿瘤能力。“不要吃我”信号（如 CD47）使肿瘤能够逃避免疫性吞噬而不受控制地生长。CD47 在多种肿瘤中表达上调，并与巨噬细胞表面的 SIRPα 相互作用，从而限制其效应功能。类似地，CD24 与 TAMs 上的 Siglec-10 结合，抑制吞噬反应。尽管巨噬细胞具有潜在治疗价值，但目前仍缺乏有效的针对性治疗手段。近期针对 CD47 的临床试验在实体瘤中显示疗效有限且伴随显著不良反应，主要原因是 CD47 在红细胞（RBC）等健康细胞上也有表达。因此，我们开发了新型的抗 CD47 重链可变结构域抗体（vHH），其具有强效的配体阻断活性且对 RBC 结合极低，并利用这些 vHH 构建了可同时阻断 CD47 与 CD24 抗吞噬信号、保留 Fc 效应功能并改善肿瘤靶向性的抗 CD47/CD24 双特异性抗体。
> 
> 方法：采用酵母展示技术分别筛选获得针对 CD47 的 vHH 以及完全人源化的抗 CD24 单克隆抗体。利用 AlphaFold3 预测 vHH 与 CD47 的抗原结合表位。对双特异性抗体进行体外设计、构建与特性鉴定。其抗肿瘤活性通过人免疫细胞重建小鼠模型评估，安全性则在人源化同系小鼠模型中检测。此外，还在离体实验中探究其作用机制及对肿瘤微环境的影响。
> 
> 结果：筛选获得了针对 CD47 的 vHH 及完全人源化的抗 CD24 抗体，均表现出强有力的配体阻断活性。以人 IgG1 骨架工程化构建的双特异性抗体 BiAb-103C 对 CD47/CD24 双阳性肿瘤细胞具有强结合力，并能有效阻断 CD47-SIRPα 相互作用。在 CD24（而非 CD47）单阳性细胞中观察到 Fc 效应活性，促进对 CD47/CD24 肿瘤细胞的吞噬及抗体依赖性细胞毒作用。在小鼠模型中，这些抗体候选物表现出显著的抗肿瘤活性和良好的安全性。
> 
> 结论：本研究发现了一种新型的抗 CD47/CD24 双特异性抗体，为解决 CD47 靶向治疗的疗效与安全性难题提供了一种有前景的治疗策略，加深了对巨噬细胞驱动免疫治疗机制的理解，并有望为对现有免疫疗法无反应的患者提供新的治疗选择。

### 第二部分 AI 大师评价

该研究旨在开发一种同时靶向 CD47 与 CD24 的双特异性抗体，以克服传统 CD47 靶向疗法疗效有限且副作用明显的挑战。研究通过酵母展示与 AlphaFold3 结构预测筛选高亲和力抗体片段，并构建保持 Fc 效应功能的双特异性抗体。结果显示，BiAb-103C 能有效阻断 CD47/SIRPα 与 CD24/Siglec-10 信号，促进巨噬细胞介导的肿瘤清除且具良好安全性。该研究创新性地整合两种“不要吃我”信号的双重阻断，为基于巨噬细胞的肿瘤免疫治疗提供了新的方向，但仍需进一步临床验证其长期安全性与疗效。

---

## 34. 空间转录组学揭示IPMN及其衍生胰腺癌的分子进展、侵袭特征与免疫图谱

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381181)
**期刊：** Gut
**PMID：** 41381181
**DOI：** 10.1136/gutjnl-2025-336117

### 第一部分 原文与翻译

**英文原标题：** Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer.

> **英文摘要：**
> BACKGROUND: Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic cancer with highly variable malignant potential. Current understanding of their biology remains incomplete, limiting accurate risk stratification and targeted interventions.
> 
> OBJECTIVE: This study aimed to characterise the molecular and immune features of IPMN across different dysplasia grades and histological subtypes, with a focus on IPMN-associated invasive carcinoma (IPMN-IC).
> 
> DESIGN: Spatial whole-transcriptome profiling using Digital Spatial Profiling was conducted on 12 patients, capturing the full histological and dysplastic spectrum of IPMN and conventional pancreatic ductal adenocarcinoma. A total of 117 epithelial, immune and stromal areas of interest were analysed. An expanded cohort of 43 patients with IPMN was used to validate selected key markers.
> 
> RESULTS: Transcriptomic analysis unveiled stage-specific molecular alterations and identified two distinct subsets of high-grade (HG) IPMN lesions: one resembling indolent lesions (HG) and the other IC (HG+). Key markers associated with divergent biological behaviours were identified, including MUC5AC and TFF1 in indolent lesions, and Claudin-1 in lesions with invasive potential. Immune profiling revealed a trajectory from activation to suppression during IPMN progression. Several characteristic immune checkpoint molecules, including CEACAM1 and CD44, were identified in IPMN-IC.
> 
> CONCLUSION: This study provides a spatially resolved molecular map of IPMN progression, delineating key transcriptomic and immune signatures. These findings advance the understanding of IPMN biology and highlight potential biomarkers for risk stratification and therapeutic strategies.

> **中文摘要：**
> 背景：导管内乳头状黏液性肿瘤（IPMN）是胰腺癌的前驱病变，具有高度可变的恶性潜能。目前对其生物学特性的理解仍不完整，限制了精确的风险分层和靶向干预。
> 
> 研究目的：本研究旨在描绘不同异型增生程度和组织学亚型的IPMN在分子及免疫特征方面的差异，重点研究与IPMN相关的侵袭性癌（IPMN-IC）。
> 
> 研究设计：研究采用数字空间转录组（Digital Spatial Profiling）技术对12例患者进行了全转录组空间分析，涵盖IPMN及常规胰腺导管腺癌的完整组织学与异型增生谱系。共分析了117个上皮、免疫及间质感兴趣区域。另有一个包含43例IPMN患者的扩展队列用于验证选定的关键标志物。
> 
> 研究结果：转录组分析揭示了分级特异的分子改变，并鉴定出两类不同的高级别（HG）IPMN病变：一类类似惰性病变（HG），另一类类似侵袭性癌（HG+）。与不同生物学行为相关的关键标志物被识别出，包括惰性病变中表达的MUC5AC和TFF1，以及具有侵袭潜能病变中表达的Claudin-1。免疫特征分析表明，在IPMN进展过程中，免疫状态经历了从激活到抑制的动态变化。在IPMN-IC中，还发现了多个特征性免疫检查点分子，包括CEACAM1和CD44。
> 
> 结论：本研究构建了一个空间分辨的IPMN进展分子图谱，清晰描绘了关键的转录组及免疫特征。这些发现深化了对IPMN生物学的理解，并为风险分层及靶向治疗策略提供了潜在生物标志物。

### 第二部分 AI 大师评价

该研究通过空间转录组学技术系统解析了IPMN及其衍生胰腺癌的分子进展与免疫演化，为理解其恶变机制提供了空间分辨的新视角。研究揭示了高级别IPMN中分子异质性及免疫由激活向抑制转变的轨迹，并识别出关键分子标志物如MUC5AC、TFF1和Claudin-1。其创新之处在于结合空间转录组与免疫分析描绘病变演进图谱。局限性在于样本量有限，仍需在更大人群中验证其生物学与临床意义。

---

## 35. 对“直肠与结肠大体无蒂息肉中黏膜下癌发生率及操作结局的比较：法国ESD注册数据”的回应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41381177)
**期刊：** Gut
**PMID：** 41381177
**DOI：** 10.1136/gutjnl-2025-337470

### 第一部分 原文与翻译

**英文原标题：** Response to 'Rectal versus colonic submucosal cancer rates and procedural outcomes in large non-pedunculated polyps: French ESD registry data'.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文为针对法国ESD注册研究结果的学术回应，探讨直肠与结肠大体无蒂息肉在黏膜下癌发生率和操作结局上的差异。文章可能对原研究方法、数据解读或临床意义进行分析与讨论，进一步深化对不同部位大息肉处理策略的理解。虽然缺少摘要限制了直接的研究细节解读，但该回应有助于推动相关领域的学术讨论与临床实践优化。

---

## 36. 晚期胃癌中仑伐替尼-帕博利珠单抗-化疗方案的关键考量：来自 LEAP-015 研究的见解

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41380117)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41380117
**DOI：** 10.1200/JCO-25-02049

### 第一部分 原文与翻译

**英文原标题：** Key Considerations for the Lenvatinib-Pembrolizumab-Chemotherapy Regimen in Advanced Gastric Cancer: Insights From LEAP-015.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究聚焦于晚期胃癌治疗中仑伐替尼、帕博利珠单抗联合化疗方案的关键临床应用要点，旨在借助 LEAP-015 研究的经验总结方案设计与疗效安全性的考量。尽管文献未提供摘要，但标题暗示其目标在于整合多靶点、多机制的治疗策略，以优化综合抗肿瘤效果。该研究可能探讨了药物间协同作用、患者选择标准及毒性管理的策略。潜在创新性体现在多机制联合治疗思路，但需更多临床验证支持其长期疗效与安全性。

---

## 37. 妊娠期癌症管理：美国临床肿瘤学会（ASCO）指南

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41380115)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41380115
**DOI：** 10.1200/JCO-25-02115

### 第一部分 原文与翻译

**英文原标题：** Management of Cancer During Pregnancy: ASCO Guideline.

> **英文摘要：**
> PURPOSE: To provide guidance on the recommended management of cancer in pregnant patients.
> 
> METHODS: A multidisciplinary Expert Panel convened and conducted a systematic review of the literature.
> 
> RESULTS: The systematic review identified 450 eligible studies. Much of the evidence consisted of observational data, case series, and case reports.
> 
> RECOMMENDATIONS: Management of cancer during pregnancy should be grounded in a values-based informed-consent process outlining maternal and fetal risks and anticipated benefits. Diagnostic evaluation should follow the as low as reasonably achievable (ALARA) principle, with timing of diagnostic studies individualized based on urgency of cancer detection, potential dangers of delay, and the balance of risks to both the pregnant patient and her embryo or fetus. Due to significant risk of harm to the developing embryo and/or fetus, systemic therapy should be deferred until the second trimester. Methotrexate, hormonal therapies, human epidermal growth factor receptor 2-targeted agents, vascular endothelial growth factor and poly (ADP-ribose) polymerase inhibitors, antibody-drug conjugates, and all cellular therapies are contraindicated during pregnancy, regardless of gestational age. For patients who wish to continue their pregnancy, delivery should be planned at or after 37 weeks, with the final chemotherapy dose scheduled 2-4 weeks before birth. Referral to psychosocial support services is essential to address emotional and practical challenges, reduce distress, and support shared decision making.Additional information is available at www.asco.org/survivorship-guidelines.

> **中文摘要：**
> 目的：为妊娠期癌症患者的推荐管理提供指导。
> 
> 方法：一个多学科专家小组召开会议，并对文献进行了系统综述。
> 
> 结果：系统综述共识别出450项符合标准的研究。大部分证据来自观察性数据、病例系列和病例报告。
> 
> 建议：妊娠期癌症的管理应基于价值导向的知情同意过程，明确母体和胎儿的风险及预期获益。诊断评估应遵循“尽量做到辐射最低可行”（ALARA）原则，诊断检查的时间应根据癌症检测的紧迫性、延迟的潜在危害，以及对孕妇及其胚胎或胎儿风险的平衡来个体化决定。由于对发育中胚胎或胎儿存在显著损害风险，系统性治疗应推迟至妊娠第二孕期。甲氨蝶呤、激素治疗、人表皮生长因子受体2（HER2）靶向药物、血管内皮生长因子及多聚（ADP-核糖）聚合酶抑制剂、抗体-药物偶联物以及所有细胞治疗在妊娠期均禁用，无论妊娠周数为何。对于希望继续妊娠的患者，应计划在孕37周或之后分娩，并在分娩前2–4周安排最后一次化疗。应转介心理社会支持服务，以应对情绪和实际挑战，减轻痛苦，并支持共同决策。更多信息可在 www.asco.org/survivorship-guidelines 获得。

### 第二部分 AI 大师评价

本指南旨在为妊娠期癌症的管理提供基于证据的临床建议，通过系统综述450项研究建立共识。其核心在于平衡母体肿瘤控制与胎儿安全，强调遵循ALARA原则和个体化诊断策略。指南明确指出系统治疗应推迟至第二孕期，并列出了妊娠期禁用药物类别。该文件在临床决策伦理、跨学科协作和患者价值取向方面具有创新性，但仍受限于现有证据多为观察性研究，缺乏大规模前瞻性数据。

---

## 38. 回复：关于在晚期胃癌中使用仑伐替尼-帕博利珠单抗-化疗方案的关键考量——来自LEAP-015研究的见解。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41380104)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41380104
**DOI：** 10.1200/JCO-25-02148

### 第一部分 原文与翻译

**英文原标题：** Reply to: Key Considerations for the Lenvatinib-Pembrolizumab-Chemotherapy Regimen in Advanced Gastric Cancer: Insights From LEAP-015.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文为作者对先前有关LEAP-015研究及其在晚期胃癌中仑伐替尼联合帕博利珠单抗与化疗方案的讨论所作的回复。虽然未提供摘要，但可以推测其重点是对治疗策略的关键考量进行澄清或补充。此类交流对于深化对复合免疫联合疗法的理解、优化临床应用决策具有较高学术价值。由于内容为回复性质，研究深度和数据阐述可能有限，但在学术对话中具重要参考意义。

---

## 39. 从基因组学视角看，惰性多发性骨髓瘤并非独立疾病实体，而是由意义未定的单克隆免疫球蛋白病或多发性骨髓瘤所组成的集合。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41380103)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41380103
**DOI：** 10.1200/JCO-25-00289

### 第一部分 原文与翻译

**英文原标题：** Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.

> **英文摘要：**
> PURPOSE: The diagnosis of smoldering multiple myeloma (SMM) primarily relies on clinical features such as plasma cell involvement, immunoglobulin protein levels, and end-organ damage. However, as early intervention becomes a priority, the role of genomic features in differentiating risk is gaining attention.
> 
> METHODS: This study analyzed next-generation sequencing data from 224 precursor condition samples with 51 patients having paired SMM and multiple myeloma (MM) and 1,779 samples from newly diagnosed MM to identify genomic features linked to progression in SMM and those with a low-risk nonprogressor precursor condition.
> 
> RESULTS: Our findings from paired samples revealed no significant differences in somatic alterations and clonal structures between SMM and MM samples from the same patient. This indicates that plasma cells in progressor SMM are genomically pre-equipped with changes that define myeloma. Over 80% of driver mutations were present at both time points, and more than 66% of progressor samples showed only minor clonal changes. We further compared genomic changes between nonprogressor and progressor SMM. Nonprogressor plasma cells showed significantly lower mutational load and the absence of copy number alterations on chromosome 8. They reduced focal genomic loss compared with progressor plasma cells. A scoring system using genomic features predictively identified patients with low-risk SMM unlikely to progress, validated on 101 additional independent samples, and additive clinical value of genomic classification was further shown in combination with 20/2/20.
> 
> CONCLUSION: In summary, the genomic distinctions now suggest that a proportion of SMMs with progressor phenotype are akin to MM, whereas nonprogressor SMM has monoclonal gammopathy of undetermined significance-like characteristics. The results should influence further investigation in larger studies to inform future diagnostic criteria and trial designs.

> **中文摘要：**
> 研究目的：惰性多发性骨髓瘤（SMM）的诊断主要依赖于临床特征，如浆细胞浸润程度、免疫球蛋白蛋白水平以及终末器官损伤。然而，随着早期干预逐渐成为重点，基因组学特征在区分风险中的作用正受到关注。
> 
> 研究方法：本研究分析了224例前驱状态样本的二代测序数据，其中51名患者具有配对的SMM与多发性骨髓瘤（MM）样本，另包括1,779例新诊断的MM样本，以识别与SMM进展及低风险未进展前驱状态相关的基因组特征。
> 
> 研究结果：对配对样本的分析发现，同一患者的SMM与MM样本之间在体细胞突变和克隆结构方面无显著差异。这表明，进展型SMM的浆细胞在基因组上已预先具备定义骨髓瘤的变化。超过80%的驱动突变在两个时间点均存在，且超过66%的进展样本仅显示轻微的克隆变化。进一步比较发现，未进展SMM的浆细胞突变负荷显著较低，且缺乏第8号染色体拷贝数变异；与进展型浆细胞相比，其局灶性基因组缺失亦更少。基于基因组特征的评分系统能够预测性地识别不易进展的低风险SMM患者，并通过额外101个独立样本进行了验证。同时，将基因组分类与20/2/20标准结合后，进一步证明了其附加的临床价值。
> 
> 研究结论：总体而言，基因组学差异表明，具有进展表型的部分SMM在本质上与MM相似，而未进展SMM则表现出类似意义未定单克隆免疫球蛋白病的特征。研究结果提示，应在更大规模的研究中进一步探讨，以指导未来诊断标准及临床试验设计。

### 第二部分 AI 大师评价

本研究旨在阐明惰性多发性骨髓瘤（SMM）的基因组学特征及其与多发性骨髓瘤（MM）和意义未定单克隆免疫球蛋白病（MGUS）之间的关系。作者通过大样本二代测序数据比较发现，进展型SMM与MM在体细胞变异和克隆结构上高度相似，而未进展型SMM则具有较低的突变负荷和更稳定的基因组特征。研究创新性地提出了一个基于基因组学的风险预测评分系统，并验证了其临床补充价值。尽管样本验证充分，但仍需在更大人群中确认这些基因组标志物的普适性。

---

## 40. 多物种泛基因组揭示群体规模对结构变异的普遍影响

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379974)
**期刊：** Science (New York, N.Y.)
**PMID：** 41379974
**DOI：** 10.1126/science.adw1931

### 第一部分 原文与翻译

**英文原标题：** Multispecies pangenomes reveal a pervasive influence of population size on structural variation.

> **英文摘要：**
> Structural variants (SVs) are widespread in vertebrate genomes, yet their evolutionary dynamics remain poorly understood. Using 45 long-read de novo genome assemblies and pangenome tools, we analyze SVs among three closely related species of North American jays (, scrub-jays) displaying a 55-fold range in effective population size. We find rapid evolution of genome architecture, including ~100-megabase decreases in genome size driven by shifts in complex satellite landscapes. SVs exhibit slightly deleterious dynamics modulated by variant length and population size, with consistent evidence of adaptive fixation only in the largest population. Gene copy number variants exhibit an inverse relationship with population size, indicating strongly deleterious dynamics, with consequences for gene expression. Our long-read dataset and pangenome analysis demonstrate how population size shapes genome complexity.

> **中文摘要：**
> 结构变异（SVs）在脊椎动物基因组中广泛存在，但其进化动力学仍知之甚少。通过45个基于长读段测序的去 novo 基因组组装和泛基因组工具，我们分析了北美三种密切相关的松鸦（scrub-jays）物种间的结构变异，这些物种的有效群体规模相差高达55倍。我们发现基因组结构发生了快速演化，包括由复杂卫星序列景观变化驱动的约1亿碱基的基因组大小缩减。结构变异表现出轻微有害的动力学特征，其效应受变异长度和群体大小的调节；仅在最大群体中观察到一致的适应性固定证据。基因拷贝数变异与群体规模呈负相关，表明其具有显著的有害动力学，并对基因表达造成影响。我们的长读段数据集和泛基因组分析揭示了群体规模如何塑造基因组复杂性。

### 第二部分 AI 大师评价

本研究旨在探讨群体规模如何影响脊椎动物基因组的结构变异进化，通过构建45个长读段去 novo 基因组并应用泛基因组分析，对北美松鸦物种间的结构变异进行了系统比较。结果显示，群体规模不仅影响基因组大小与卫星序列构成，还调节结构变异的选择动力学。研究揭示了群体规模与基因拷贝数变异呈负相关的普遍规律，为理解基因组复杂性进化机制提供了坚实证据。尽管样本集中在特定鸟类系统，但其方法框架对其他脊椎动物群体遗传研究具有广泛启示意义。

---

## 41. 肝白血病因子调控促炎性记忆性CD4 T细胞的组织驻留性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379973)
**期刊：** Science (New York, N.Y.)
**PMID：** 41379973
**DOI：** 10.1126/science.adp0714

### 第一部分 原文与翻译

**英文原标题：** Hepatic leukemia factor directs tissue residency of proinflammatory memory CD4 T cells.

> **英文摘要：**
> CD4 tissue-resident memory T (T) cells contribute to host defense and to the pathogenesis of chronic inflammatory diseases, but the molecules that direct their differentiation are unknown. We found that the transcription factor hepatic leukemia factor (HLF) could direct the tissue residency program and function of CD4 T cells. HLF simultaneously up-regulated tissue retention receptors, down-regulated tissue egress receptors, and promoted proinflammatory CD4 T cells by inducing , and all of these processes were associated with changes in chromatin accessibility. Genetic deletion of  inhibited CD4 T cell generation and ameliorated airway tissue inflammation in vivo. HLF CD4 T cells isolated from inflamed airway tissue in humans had a tissue residency signature and expressed inflammatory cytokines. We conclude that HLF may act as a central regulator of proinflammatory CD4 T cell development and function.

> **中文摘要：**
> CD4 组织驻留记忆T细胞（T细胞）参与宿主防御并促进慢性炎症性疾病的发病过程，但调控其分化的分子机制尚不清楚。我们发现转录因子肝白血病因子（HLF）能够指导CD4 T细胞的组织驻留程序及其功能。HLF可同时上调组织滞留受体、下调组织外迁受体，并通过诱导促炎性CD4 T细胞的相关分子促进其形成，这些过程均与染色质可及性变化有关。基因敲除实验表明，缺失HLF会抑制CD4 T细胞的生成，并在体内减轻气道组织炎症。来自人类炎症性气道组织的HLF CD4 T细胞呈现组织驻留特征并表达炎症性细胞因子。我们得出结论，HLF可能是促炎性CD4 T细胞发育和功能的核心调控因子。

### 第二部分 AI 大师评价

本研究旨在解析促炎性记忆CD4 T细胞组织驻留性的分子调控机制。作者通过小鼠模型和人类样本发现，转录因子HLF调节T细胞的组织驻留与炎症活性，其缺失可缓解组织炎症。这一发现揭示了HLF在组织免疫稳态和慢性炎症中的关键作用，拓展了对免疫细胞局部持留机制的理解。研究创新性地将HLF定位为潜在的免疫调控靶点，但其具体下游通路及临床可转化性仍需进一步验证。

---

## 42. 体内生成的抗癌细胞帮助患者战胜疾病

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379962)
**期刊：** Science (New York, N.Y.)
**PMID：** 41379962
**DOI：** 10.1126/science.aee6253

### 第一部分 原文与翻译

**英文原标题：** Cancer-fighting cells made in body help patients.

> **英文摘要：**
> Approach could be faster than making CAR-T cells in the lab-and early results are encouraging.

> **中文摘要：**
> 这种方法可能比在实验室制造CAR-T细胞更为迅速——早期结果令人鼓舞。

### 第二部分 AI 大师评价

该研究探索了一种直接在患者体内生成抗癌细胞的新策略，以提高细胞治疗的效率和可及性。与在实验室外制备CAR-T细胞的传统流程相比，这种体内生成方式在时间和成本上具备明显优势。初步结果表明该方法具有潜在疗效，显示出临床应用的希望。然而，其长期安全性、精确性及可控性仍需进一步验证。整体而言，该研究为免疫细胞疗法开辟了新的技术路径。

---

## 43. 癌症中的染色体粉碎现象

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379961)
**期刊：** Science (New York, N.Y.)
**PMID：** 41379961
**DOI：** 10.1126/science.aed1825

### 第一部分 原文与翻译

**英文原标题：** Chromosome shattering in cancer.

> **英文摘要：**
> A protein that cuts double-stranded DNA contributes to chromosome scrambling in human cancer cells.

> **中文摘要：**
> 一种能够切割双链DNA的蛋白质会促进人类癌细胞中的染色体重排。

### 第二部分 AI 大师评价

该研究揭示了一种可切割双链DNA的蛋白在癌细胞染色体重排中的关键作用，提出了染色体粉碎现象的新机制。研究暗示基因组不稳定性可能部分源于特定DNA切割酶的异常活化，为理解癌症的遗传异质性提供了新的视角。尽管摘要中未提及具体的实验方法，但这一发现为癌症基因组结构变异的研究和潜在靶向干预开辟了新方向。

---

## 44. 由N4BP2核酸内切酶介导的胞质暴露染色体断裂所引发的染色体碎裂与环外染色体形成

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379955)
**期刊：** Science (New York, N.Y.)
**PMID：** 41379955
**DOI：** 10.1126/science.ado0977

### 第一部分 原文与翻译

**英文原标题：** Chromothripsis and ecDNA initiated by N4BP2 nuclease fragmentation of cytoplasm-exposed chromosomes.

> **英文摘要：**
> Genome instability, including chromothripsis, is a hallmark of cancer. Cancer cells frequently contain micronuclei-small, nucleus-like structures formed by chromosome missegregation-that are susceptible to rupture, exposing chromatin to cytoplasmic nucleases. Through an unbiased, imaging-based small interfering RNA screen that targeted all 204 known and putative human nucleases, we identified a previously uncharacterized cytoplasmic endonuclease, NEDD4-binding protein 2 (N4BP2), that enters ruptured micronuclei and initiates DNA damage, leading to chromosome fragmentation. N4BP2 promoted genome rearrangements (including chromothripsis), formation of extrachromosomal DNA (ecDNA) in drug-induced gene amplification, tumorigenesis, and tumor cell proliferation in an induced model of human high-grade glioma. Analysis of more than 10,000 human cancer genomes revealed elevated N4BP2 expression to be predictive of chromothripsis and copy number amplifications, including ecDNA.

> **中文摘要：**
> 包括染色体碎裂在内的基因组不稳定性是癌症的标志之一。癌细胞中常可见微核——由染色体分离错误形成、形似细胞核的小型结构——这些微核易发生破裂，使染色质暴露于胞质核酸酶之下。通过一项无偏倚、基于成像的小干扰RNA筛选（覆盖全部204种已知和推定的人源核酸酶），我们鉴定出一种此前未被表征的胞质内切酶，即NEDD4结合蛋白2（N4BP2）。该酶可进入破裂的微核，诱导DNA损伤并导致染色体断裂。N4BP2促进了基因组重排（包括染色体碎裂）、药物诱导的基因扩增中环外DNA（ecDNA）的形成、肿瘤发生及肿瘤细胞增殖，在人高等级胶质瘤的诱导模型中亦有体现。对超过一万例人类癌症基因组的分析显示，N4BP2的高表达可预测染色体碎裂及拷贝数扩增（包括环外DNA）的发生。

### 第二部分 AI 大师评价

本研究揭示了N4BP2作为一种新型胞质内切酶，在微核破裂后进入胞质并诱导染色体断裂，从而驱动染色体碎裂与环外DNA形成的关键作用。研究结合RNA筛选、成像分析及癌症基因组学证据，系统解析了N4BP2与基因组不稳定性及肿瘤生物学之间的因果联系。该发现不仅丰富了对染色体碎裂机制的理解，也将N4BP2标定为一个潜在的癌症治疗靶点。其局限在于目前的机制验证多基于模型系统，临床因果关系尚需进一步探索。

---

## 45. 哺乳动物小脑中AMPA受体-TARP复合物的结构与组织特征

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379938)
**期刊：** Science (New York, N.Y.)
**PMID：** 41379938
**DOI：** 10.1126/science.aeb3577

### 第一部分 原文与翻译

**英文原标题：** Structure and organization of AMPA receptor-TARP complexes in the mammalian cerebellum.

> **英文摘要：**
> AMPA receptors (AMPARs) are multimodal transducers of glutamatergic signals throughout the brain. Their diversity is exemplified in the cerebellum; at afferent synapses, AMPARs mediate high-frequency excitation, whereas in Bergmann glia (BG) they support calcium transients that modulate synaptic transmission. This spectrum arises from different combinations of core subunits (GluA1-4), auxiliary proteins, and post-transcriptional modifications. Here, using mass-spectrometry, cryo-EM, and electrophysiology, we characterize major cerebellar AMPARs in pig: calcium-impermeable GluA2/A4 heteromers with four TARP subunits, mainly neuronal in origin, and BG-specific calcium-permeable GluA1/A4 heteromers containing two Type-2 TARPs. We also showed that GluA4 receptors consistently exhibit compact N-terminal domains that promote their synaptic delivery. Our study defines the organizational principles of mammalian cerebellar AMPAR complexes and reveals how different receptor subtypes support cell-type specific functions.

> **中文摘要：**
> AMPA受体（AMPARs）是遍布全脑的多模态谷氨酸信号转导器。它们的多样性在小脑中表现尤为突出；在传入突触处，AMPAR介导高频兴奋，而在伯格曼胶质细胞（BG）中，它们支持可调节突触传递的钙瞬变。这种多样性来源于不同核心亚基（GluA1-4）、辅助蛋白及转录后修饰的组合。在本研究中，我们利用质谱分析、冷冻电镜以及电生理学等技术，对猪小脑的主要AMPAR进行了表征：鉴定出来源于神经元的钙不可渗透型GluA2/A4异源复合体（含四个TARP亚基），以及BG特异的钙可渗透型GluA1/A4异源复合体（含两个Ⅱ型TARP）。此外，我们发现GluA4受体一致呈现紧凑的N端结构域，这有助于其突触定位。我们的研究明确了哺乳动物小脑AMPAR复合物的组织原则，并揭示了不同受体亚型如何支撑特定细胞类型的功能。

### 第二部分 AI 大师评价

本研究系统揭示了哺乳动物小脑中AMPA受体-TARP复合物的结构组成与功能分化，结合质谱、冷冻电镜及电生理等多模态手段，描绘了神经元与胶质细胞AMPAR的亚型特征。结果揭示了GluA2/A4与GluA1/A4异源复合体在离子通透性与TARP构成上的显著差异，并指出GluA4受体的结构特征与突触传递调控密切相关。该工作为理解小脑突触多样性及神经胶质互作的分子基础提供了新框架，同时提示结构差异在细胞类型特异性信号中的关键作用。

---

## 46. 宫颈癌神经周围侵犯的多组学综合特征揭示诊断标志物、分子驱动因子及治疗策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379570)
**期刊：** Cancer research
**PMID：** 41379570
**DOI：** 10.1158/0008-5472.CAN-25-0149

### 第一部分 原文与翻译

**英文原标题：** Comprehensive Multi-Omic Characterization of Perineural Invasion in Cervical Cancer Reveals Diagnostic Markers, Molecular Drivers, and Therapeutic Strategies.

> **英文摘要：**
> Perineural invasion (PNI) is an important pathological feature of cervical cancer that is associated with poor prognosis and provides key information for clinical decisions. A better understanding of the molecular mechanisms underlying PNI could lead to improved patient treatment strategies. Here, we generated whole-exome, whole-genome, and RNA-sequencing data from tumors and matched normal clinical samples of 45 cervical cancer patients and performed a comparative analysis between 23 PNI and 22 non-PNI tumors. A robust machine learning approach identified a three-gene expression signature of MT1G, NPAS1, and SPRY1 that could predict the tumor PNI status with high accuracy, which was validated using an independent cohort (18 PNI and 19 non-PNI). Loss-of-function FBXW7 mutations were identified as driver events for PNI that lead to increased MYC activity and an immunosuppressive tumor microenvironment. Finally, a deep-learning model for predicting the drug efficacy over patients' transcriptomic data revealed OTX015, a BET inhibitor, as a promising treatment that targets mutated FBXW7 PNI tumors. This study provides a rich resource for elucidating the molecular mechanisms of PNI tumors, laying a critical foundation for developing effective diagnostic and therapeutic strategies for PNI tumors in cervical cancer.

> **中文摘要：**
> 神经周围侵犯（PNI）是宫颈癌的重要病理学特征，与不良预后相关，并为临床决策提供关键信息。深入理解PNI的分子机制可能有助于改善患者的治疗策略。本研究从45例宫颈癌患者的肿瘤及配对正常临床样本中获取了全外显子组、全基因组及RNA测序数据，并比较分析了23例PNI阳性与22例PNI阴性肿瘤。通过一种稳健的机器学习方法，发现MT1G、NPAS1和SPRY1构成的三基因表达特征可高精度预测肿瘤的PNI状态，并在独立队列（18例PNI阳性与19例PNI阴性）中得到了验证。进一步确定丧失功能的FBXW7突变是PNI的驱动事件，导致MYC活性增强及免疫抑制性肿瘤微环境的形成。最后，基于患者转录组数据的深度学习药效预测模型揭示，作为BET抑制剂的OTX015可作为一种有潜力的治疗方案，靶向突变FBXW7的PNI肿瘤。本研究为阐明PNI肿瘤的分子机制提供了丰富资源，并为宫颈癌PNI肿瘤的有效诊断与治疗策略的开发奠定了关键基础。

### 第二部分 AI 大师评价

本研究以多组学方法系统解析了宫颈癌神经周围侵犯的分子基础与潜在治疗靶点。研究结合全基因组、外显子组及转录组数据，并通过机器学习识别出具有诊断价值的三基因特征MT1G、NPAS1、SPRY1。发现FBXW7功能丧失突变促进了PNI的发生，揭示其通过MYC驱动的免疫抑制机制作用。研究通过深度学习预测进一步提出BET抑制剂OTX015作为潜在靶向药物，具有一定创新性。局限性在于样本量较有限及对临床疗效验证的缺乏，但为PNI机制与精准诊疗提供了重要基础。

---

## 47. 转录组可塑性是转移性胰腺癌的标志特征

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41379552)
**期刊：** Cancer research
**PMID：** 41379552
**DOI：** 10.1158/0008-5472.CAN-25-1117

### 第一部分 原文与翻译

**英文原标题：** Transcriptomic Plasticity is a Hallmark of Metastatic Pancreatic Cancer.

> **英文摘要：**
> Metastasis is the leading cause of cancer deaths. To develop strategies for intercepting metastatic progression, a better understanding of how tumor cells adapt to vastly different organ contexts is needed. To investigate this question, a single-cell transcriptomic atlas of primary tumor and diverse metastatic samples (liver, omentum, peritoneum, stomach wall, lymph node, and diaphragm) from a patient with pancreatic ductal adenocarcinoma who underwent rapid autopsy was generated. Using unsupervised archetype analysis, both shared and site-specific gene programs were identified, including lipid metabolism and gastrointestinal programs prevalent in peritoneal and stomach wall lesions, respectively. We developed PICASSO as a probabilistic approach for inferring clonal phylogeny from single-cell and matched whole-exome sequencing data. Comparison of PICASSO-generated clonal structure with phenotypic signatures revealed that pancreatic cancer cells adapted to local environments with minimal contribution from clonal genotype. Our results suggest a paradigm whereby strong environmental effects are imposed on highly plastic cancer cells during metastatic dissemination.

> **中文摘要：**
> 转移是癌症死亡的主要原因。为了制定阻断转移进程的策略，需要更深入地理解肿瘤细胞如何适应截然不同的器官环境。为探究这一问题，研究者构建了一位接受快速尸检的胰腺导管腺癌患者的单细胞转录组图谱，涵盖原发肿瘤及多种转移样本（肝脏、大网膜、腹膜、胃壁、淋巴结和膈肌）。通过无监督原型分析，鉴定出共有及部位特异性的基因程序，包括分别在腹膜和胃壁转移灶中常见的脂质代谢与胃肠道相关程序。研究团队开发了 PICASSO，这是一种基于概率的方法，可通过单细胞及匹配的全外显子测序数据推断克隆系统发生。将 PICASSO 推断的克隆结构与表型特征进行比较发现，胰腺癌细胞在局部环境中的适应主要依赖于表型可塑性，而非克隆基因型。研究结果提出了一种新范式，即在转移扩散过程中，强烈的环境效应作用于高度可塑的癌细胞。

### 第二部分 AI 大师评价

本研究旨在阐明胰腺癌细胞在不同转移部位的转录组可塑性及其适应机制。通过单细胞转录组图谱和新开发的 PICASSO 推断模型，研究团队揭示了肿瘤细胞在强烈的环境压力下展现出高度表型可塑性，而克隆基因型差异贡献有限。这一发现强调了微环境在转移适应中的主导作用，为未来靶向癌细胞可塑性以阻断转移提供了新思路。研究方法创新性强，但样本来源单一及推断模型的普适性仍需进一步验证。

---

速递结束，祝您工作愉快！